ArticlePDF AvailableLiterature Review

Abstract

Acne vulgaris is a chronic inflammatory disease — rather than a natural part of the life cycle as colloquially viewed — of the pilosebaceous unit (comprising the hair follicle, hair shaft and sebaceous gland) and is among the most common dermatological conditions worldwide. Some of the key mechanisms involved in the development of acne include disturbed sebaceous gland activity associated with hyperseborrhoea (that is, increased sebum production) and alterations in sebum fatty acid composition, dysregulation of the hormone microenvironment, interaction with neuropeptides, follicular hyperkeratinization, induction of inflammation and dysfunction of the innate and adaptive immunity. Grading of acne involves lesion counting and photographic methods. However, there is a lack of consensus on the exact grading criteria, which hampers the conduction and comparison of randomized controlled clinical trials evaluating treatments. Prevention of acne relies on the successful management of modifiable risk factors, such as underlying systemic diseases and lifestyle factors. Several treatments are available, but guidelines suffer from a lack of data to make evidence-based recommendations. In addition, the complex combination treatment regimens required to target different aspects of acne pathophysiology lead to poor adherence, which undermines treatment success. Acne commonly causes scarring and reduces the quality of life of patients. New treatment options with a shift towards targeting the early processes involved in acne development instead of suppressing the effects of end products will enhance our ability to improve the outcomes for patients with acne.
Acne vulgaris is a chronic inflammatory disease of the
pilosebaceous unit (comprising the hair follicle, hair shaft
and sebaceous gland; FIG.1) and is among the most com-
mon dermatological conditions worldwide, with an esti-
mated 650million people affected1,2. Acne is considered a
chronic disease owing to its prolonged course, pattern of
recurrence and relapse, and manifestations such as acute
outbreaks or slow onset. Moreover, acne causes profound
negative psychological and social effects on the quality
oflife of patients3.
Although progress has been made in understand-
ing the pathophysiology of acne and the mechanisms
of actions of available drugs to treat the disease, many
unanswered questions remain. The lack of a consensus
grading system also slows efforts to compare efficacies of
different medications in clinical studies, which is imped-
ing the formulation of a globally approved consensus
guideline. Given that abnormalities in several processes
(sebum production and sebocyte differentiation, prolif-
eration and inflammation) can contribute to the devel-
opment of acne, a multipronged treatment regimen is
needed in most patients. This complex regimen impairs
adherence, which is key for treatment success. Acne com-
monly results in scarring and post-inflammatory hyper-
pigmentation, which has a subsequent impact on quality
of life; hence, early and aggressive therapy is crucial.
Novel delivery strategies for and modifications of exist-
ing drugs are recent changes in acne treatment, in addi-
tion to the development of new medications that target
regulatory pathways involved in acne pathophysiology
instead of suppressing the effects of the end products of
these pathways. With myriad treatment options avail-
able, including oral isotretinoin (an agent that blocks all
the pathophysiological pathways of acne and has excel-
lent adherence but is associated with severe teratogeni-
city), and several new therapies in development, better
treatment options may be available for patients soon. In
this Primer, we describe the following aspects of acne
vulgaris: epidemiology, pathophysiology, diagnostic
methods, available medications and new t reatments, patient
quality of life and adherence to treatment.
Epidemiology
Most people experience acne during adolescence, with
>95% of teenage boys and 85% of teenage girls affected4,5.
Almost 20% of these young people have moderate-to-
severe acne6 (TABLE1), and as many as 50% continue to
suffer from acne in adulthood6,7. A systematic analysis
for the Global Burden of Disease study indicated that
acne was the eighth most prevalent disease globally in
2010, following only two other skin disease categories
on the list2 (FIG.2).
Correspondence to S.R.F.
e-mail: sfeldman@
wakehealth.edu
Center for Dermatology
Research, Department of
Dermatology, Wake Forest
School of Medicine,
4618Country Club Road,
Winston-Salem,
NorthCarolina 27104, USA.
Article number: 15029
doi:10.1038/nrdp.2015.29
Published online
17 September 2015
Acne vulgaris
Sara Moradi Tuchayi1, Evgenia Makrantonaki2–4, Ruta Ganceviciene2,5, Clio Dessinioti2,6,
Steven R.Feldman1,7,8 and Christos C.Zouboulis2
Abstract | Acne vulgaris is a chronic inflammatory disease — rather than a natural part of the life cycle as
colloquially viewed — of the pilosebaceous unit (comprising the hair follicle, hair shaft and sebaceous
gland) and is among the most common dermatological conditions worldwide. Some of the key mechanisms
involved in the development of acne include disturbed sebaceous gland activity associated with
hyperseborrhoea (that is, increased sebum production) and alterations in sebum fatty acid composition,
dysregulation of the hormone microenvironment, interaction with neuropeptides, follicular hyperkeratin-
ization, induction of inflammation and dysfunction of the innate and adaptive immunity. Grading of acne
involves lesion counting and photographic methods. However, there is a lack of consensus on the exact
grading criteria, which hampers the conduction and comparison of randomized controlled clinical trials
evaluating treatments. Prevention of acne relies on the successful management of modifiable risk factors,
such as underlying systemic diseases and lifestyle factors. Several treatments are available, but guidelines
suffer from a lack of data to make evidence-based recommendations. In addition, the complex combination
treatment regimens required to target different aspects of acne pathophysiology lead to poor adherence,
which undermines treatment success. Acne commonly causes scarring and reduces the quality of life of
patients. New treatment options with a shift towards targeting the early processes involved in acne
development instead of suppressing the effects of end products will enhance our ability to improve the
outcomes for patients with acne.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
1
© 2015 Macmillan Publishers Limited. All rights reserved
Acne is the most commonly diagnosed skin condition
in the United States according to the 2010 National
Ambulatory Medical Care Survey (NAMCS) factsheet
for dermatology8, and accounts for more than 5 million
visits to physicians each year9. Acne was the most com-
mon condition seen by dermatologists in the United States
and the thirteenth most common condition by non-
dermatologists, resulting in the second most common
reason for referrals to dermatologists10; corresponding
data from other countries is lacking. Approximately two-
thirds of dermatology visits for acne are made by women11.
The mean age of patients with acne seeking treatment is
24years12, and one-third of total consultations for acne are
made by patients >25years of age13. When NAMCS data
were analysed according to specific age groups per diag-
nosis by dermatologists and by general practitioners dur-
ing skin disease-related appointments (1993–2010), acne
was the most frequent diagnosis for patients 5–44years of
age14. The mean age of children (age range: 6–18years)
seeking treatment for acne has decreased from 15.8years
in 1979 to 15.0years in 2007. This observation might be
indicative of an earlier onset of acne, which is in line with
the observation that puberty is also progressively starting
at an earlier age; however, the availability of better treat-
ment options may also have a role15. Currently, children as
young as 6–8years of age are seeking treatment15.
Not only is acne the most common dermatological
diagnosis in the overall population but it is also the most
common dermatological diagnosis in patients with skin
of colour. In the United States, acne is the most com-
monly diagnosed condition in African-American, Asian
and Hispanic patients presenting to the dermatolo-
gist, whereas the top dermatological diagnosis in white
patients is actinic keratosis16. Acne has been reported to be
more prevalent among black and Hispanic women than
in white, Asian and Continental Indian women17. Given
that acne is so prevalent, it has a high associated cost
— estimated in 2004 in the United States at >US$3bil-
lion of total direct and indirect cost and approximately
US$12billion of intangible cost because of the quality of
life impact (estimated using willingness to pay)18.
Mechanisms/pathophysiology
Acne develops in the pilosebaceous unit (FIG.1) and
involves many processes (FIG.3). Some of the key features
underlying acne development include disturbed seba-
ceous gland activity associated with hyper seborrhoea
(excessive sebum) and alterations in sebum fatty acid
composition, dysregulation of the hormone micro-
environment, interaction with neuropeptides, follicu-
lar hyperkeratinization, induction of inflammation and
dysfunction of the innate and adaptive immunity. These
processes impair functioning of the pilo sebaceous
unit, which leads to the transition of a normal pore
to microcomedones, and further to comedones and
inflammatory lesions. Bacterial antigens can potenti-
ate the inflammatory process19–21. Genetic studies of
hetero zygous and homozygous twins and family stud-
ies have produced a growing body of evidence for the
role of hereditary factors in the risk of acne develop-
ment22–24. Acne can also be triggered or worsened by, for
example, ultraviolet radiation and other environmental
factors25,26, dietary factors27,28, smoking29, stress and the
modern lifestyle30.
Sebum
Sebum is secreted by the sebaceous gland and comprises
an oily mixture of triglycerides, wax esters, squalene, free
fatty acids and small amounts of cholesterol, cholesterol
esters and diglycerides. Sebum production is regulated
by many factors that activate pathways involved in cell
proliferation and differentiation, lipogenesis, hormone
metabolism, and cytokine and chemokine release31
(FIG.4). Sebaceous lipogenesis is more complex than
previously thought, as ligand-independent, MYCN-
mediated hyperactivation of epidermal growth factor
receptor and induction of perilipins — a major group
of proteins that coat lipid droplets — may also regu-
late sebocyte differentiation and lipid production32–34.
Excessive sebum is thought to be a key contributor to
acne development. However, not all patients with acne
experience hyperseborrhoea. In fact, the correlation
between sebum production and acne severity depends
on age and sex35–37; in men, acne is more dependent on
sebum production35.
Acne is also associated with alterations in the free fatty
acid composition of sebum. Sebum of patients with acne
contains less essential (that is, fatty acids that cannot be
synthesized by the body and can only be acquired from
the diet) free fatty acids (including linoleic acid) than
that of people without acne38,39. Pro-inflammatory sebum
lipid fractions (monounsaturated fatty acids (MUFAs)
and lipoperoxides; see below) have been associated with
the development of acne lesions, and the skin surface
lipid oxidant to antioxidant ratio is another acne stimu-
lus40. Specifically, sebum of patients with acne contains
lipoperoxides resulting from the peroxidation of the lipid
squalene41. Both lipoperoxides and MUFAs influence
keratinocyte proliferation and differentiation, contribut-
ing to follicular hyperkeratinization41,42. Different ethnic
groups have different lipid profiles; for example, specific
wax ester lipid fractions differ in quantity between white
and African Americans43.
Author addresses
1Center for Dermatology Research, Department of
Dermatology, Wake Forest School of Medicine,
4618Country Club Road, Winston-Salem,
North Carolina27104, USA.
2Departments of Dermatology, Venereology, Allergology
and Immunology, Dessau Medical Center, Dessau, Germany.
3Department of Dermatology and Allergology, Ulm
University, Ulm, Germany.
4Research Group Geriatrics, Charité Universitaetsmedizin
Berlin, Berlin, Germany.
5Clinic of Infectious, Chest Diseases, Dermatovenereology
and Allergology, Vilnius University, Lithuania.
6Andreas Syngros Hospital, National and Capodistrian
University of Athens, Athens, Greece.
7Department of Pathology, Wake Forest School of
Medicine, Winston-Salem, North Carolina, USA.
8Department of Public Health Sciences, Wake Forest
School of Medicine, Winston-Salem, North Carolina, USA.
PRIMER
2
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
Systemic and local hormonal imbalance
Whether the primary abnormality causing acne is in the
level of circulating hormones or in the processing of hor-
mones in the peripheral tissue is debated. Typically, acne
starts during puberty when the hormone balance starts
to change dramatically.
In a cross-sectional, retrospective study, the andro-
genic hormone profile of 835 female patients with
acne >15years of age was analysed. In the 54.6% of
participants with signs of hyperandrogenism, the lev-
els of dehydroepiandrosterone (DHEA) were most
frequently elevated44. In a recent cross-sectional study,
andro stenedione and testosterone levels were higher
(P < 0.0001) in patients with acne than in healthy con-
trols. In addition, 17α-hydroxyprogesterone levels were
higher in male patients with acne than in healthy controls;
high levels of this androgen were associated with greater
acne severity. By contrast, 17α-hydroxyprogesterone
levels were not different in women with or without
acne, although studies are needed to investigate whether
17α-hydroxyprogesterone levels can be modulated with
adrenocorticotropin treatment. Furthermore, high
oestradiol levels in women had a protective effect45,46.
In addition to systemic changes in hormone levels,
local overproduction of steroids, in particular andro-
gens, is associated with acne. Sebocytes produce ster-
oid hormones including androgens (testosterone and
5α-dihydrostestosterone (5α-DHT)), oestrogens (oestra-
diol and oestrone) and glucocorticoids (corticosterone
and cortisol)47 (FIG.4). Cutaneous steroid production can
be regulated by locally produced corticotropin-releasing
hormone, adrenocorticotropic hormone or cytokines47–49.
Patients with acne produce more testosterone and
5α-DHT in their skin than healthy controls50, which
enhances sebaceous gland activity51,52 and stimulates
sebocyte function, respectively40. However, testosterone
affects human sebocyte proliferation in a dose-dependent
manner invitro, but not lipid syn thesis53,54. This finding
suggests that other factors might influence the seba-
ceous gland55, with peroxisome proliferator-activated
receptors (PPARs; see below) and their ligands being the
primary candidates53,54. In sebaceous glands, changes in
the expression of 17β-hydroxysteroid dehydrogenases,
the group of enzymes involved in the interconversion of
oestradiol, oestrone, testosterone and androstenedione,
can influence the expression of genes involved in lipo-
genesis56. Moreover, the expression of 17β-hydroxysteroid
dehydrogenases is negatively correlated with the expres-
sion of PPARγ — one of the key induction factors of
adipocyte differentiation56.
Glucocorticoids also regulate the production of
sebum. Enzymes catalysing the conversion of cortisone
to active cortisol are highly expressed in keratinocytes,
fibroblasts and sebaceous glands, and are upregulated
in acne lesions47. In the SZ95 sebocyte cell line, dexa-
methasone treatment enhances lipid synthesis, partially
through the transcriptional induction of sterol regulatory
element-binding transcription factor1 (SREBF1; which
b
Nature Reviews | Disease Primers
Hair
Skin
surface
Follicle
Sebaceous
gland
Follicular
orifice
a
d
c
f
e
h i
g
Normal hair follicle
Enlargement
of follicle
opening
Bacteria
Whitehead
Whitehead comedone
Blackhead comedone
Blackhead
White
blood cells
Inflammation
Papule
Pustule Nodule or cyst
Figure 1 | Acne formation. Schematic representation of
the skin containing a sebaceous unit (parta) comprising
the hair follicle and the sebaceous gland, which is
responsible for sebum production. Acne formation starts
when sebum and keratinous material shed from the skin
clog up a pore and trigger bacterial colonization, leading
to a closed or whitehead comedone (partb). As the
whitehead comedone continues to expand, owing to more
accumulation of sebum and keratinous material, the
follicular orifice opens and forms an open or blackhead
comedone (partc). The black colour is the result of oxidized
lipids and the skin pigment melanin. More distension of the
comedone results in follicular rupture and inflammatory
lesions such as papules (partd), pustules (parte) and
nodules or cysts (partf). Nodular acne is sometimes
inaccurately referred to as ‘cystic’ or ‘nodulocystic’ acne.
An acne cyst is not a true cyst as true cysts are linedby
epithelium. Histological images of a pilosebaceous unit
(partg), a comedone (parth) and an inflammatory lesion
with rupture of the follicular walls (parti) are shown. Parts
g–i reproduced with permission from REF.242, Wiley.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
3
© 2015 Macmillan Publishers Limited. All rights reserved
encodes SREBP1) and by increasing Toll-like receptor2
(TLR2) mRNA levels57.
Adult women and men with acne have increased
serum levels of insulin-like growth factor 1 (IGF1). In
women, serum IGF1 levels are correlated with the num-
ber of acne lesions, facial sebum excretion rate in post-
adolescent patients and serum levels of 5α-DHT and
DHEA sulfate58–60. IGF1 is detected in maturing sebocytes
and suprabasal sebaceous duct cells61. Animal studies
have shown that IGF1 stimulates sebocyte differentia-
tion62. By contrast, in humans, IGF1 stimulates keratino-
cyte proliferation63 and lipid synthesis46,64 by inducing
SREBF1 (REF.64) through the phosphoinositide3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK)
signal transduction pathways65.
In addition to glucocorticoids and IGF1, other factors
regulate SREBF1 levels. A high glycaemic Western diet
and high dairy protein consumption are correlated with
activation of IGF1 signalling and the promotion of mam-
malian target of rapamycin (mTOR) signalling66. mTOR
complex 1 has a crucial role in the PPARγ-stimulated
lipid uptake and differentiation of sebocytes67 while at
the same time promoting lipid production by activating
SREBP1 (REF.68). Oestrogens might have an indirect IGF1
effect on the pathogenesis of acne46. Androgens rapidly
induce SREBP1 in animal models69. Testosterone only
induces the phosphorylation of mTOR in human sebo-
cytes in the presence of IGF1 (REF.56), suggesting that
local androgen production with circulating IGF1 has a
pivotal role in sebum synthesis andacne.
Neuropeptides
The sebaceous gland expresses functional receptors
for several neuropeptides, including the receptor for
corticotropin-releasing hormone70, melanocortins71,
β-endorphin, vasoactive intestinal polypeptide, neuro-
peptide Y and calcitonin gene-related peptide72.
Activation of these receptors in human sebocytes modu-
lates the production of cytokines, cell proliferation and
differentiation, lipogenesis and androgen metabolism.
SubstanceP, which can be elicited by stress, may stimu-
late the proliferation of sebaceous precursor cells and
increase sebaceous cell size. These observations suggest
that substanceP promotes the proliferation and differ-
entiation of sebaceous glands. The facial skin of patients
with acne is highly innervated, with a higher number
of substanceP-containing nerves and mast cells, and
strong expression of neutral endopeptidase — involved
in the degradation of substanceP — in sebaceous glands
compared with patients without acne73. Endopeptidase
inhibitors may have a therapeutic role inacne74.
Inflammation cascades
Whether hyperkeratinization of the follicular duct pre-
cedes the onset of inflammation or vice versa is debated75.
The finding that IL-1 activity was found to be increased
around uninvolved follicles before the observation of
keratinocyte hyperproliferation and activation suggests
an inflammatory trigger76,77. Indeed, once inflamma-
tion is established, inflammatory acne lesions upregulate
numerous genes, including those that encode matrix
metalloproteinases, β-defensin 4, IL-8 and granulysin78.
Nuclear factor-κB (NF-κB) is also activated in acne
lesions79, as are the NF-κB-regulated cytokines such as
IL-1β, IL-8, IL-10 and tumour necrosis factor (TNF)80.
TNF induces lipogenesis through JNK, PI3K and AKT
pathways81. Increased levels of IL-8 attract inflamma-
tory cells, including polymorphonuclear leukocytes and
lymphocytes79. IL-17A-positive Tcells and Thelper17
(TH17)-related cytokines are present in acne lesions and
might have a pivotal role in the disease82.
The levels and metabolic pathways of several inflam-
matory lipid mediators are also abnormal in acne lesions.
Prostaglandins are synthesized by the cyclooxygenase
(COX) enzymes. Sebocytes express both COX isozymes,
COX1 and COX2, and COX2 expression is selectively
upregulated in sebaceous glands of patients with acne83.
Activation of the platelet-activating factor signal-
ling pathway can regulate the levels of COX2, prosta-
glandinE2 and IL-8 in SZ95 sebocytes84. Transgenic
overexpression of Cox2 in the basal epidermis of mice
leads to increased prostaglandin E2 levels, which results
in sebaceous gland hyperplasia and excessive sebum pro-
duction. This observation suggests that COX2-mediated
prostaglandin E2 synthesis could be involved in acne.
In addition, PPARγ induces COX2, and increased
PPARγ activity might further exacerbate this system85,86.
Leukotrienes are pro-inflammatory lipid mediators that
function as neutrophil attractants. Human sebocytes
express the enzymes needed for leukotriene production,
including lipooxygenases and leukotrieneA4 hydrolase.
Treatment of sebocytes with arachidonic acid stimulates
lipooxygenase expression and induces leukotrieneB4
synthesis83. Arachidonic acid also induces IL-6 and
IL-8. LeukotrieneA4 hydrolase and 5-lipooxygenase are
expressed at a higher level in acne lesions than in normal
Table 1 | Classification of clinical forms of acne vulgaris
Acne
severity
Clinical type Comedones Papules and/
or pustules
Nodules Nodules, cysts
and sinus
tracts
Mild Comedonal acne and
papulopustular acne
Comedones are the
main lesions (<20*)
Small and few in
number (<10*)
None None
Moderate Papulopustular acne and nodular
acne
10–40* 10–40* 0–10* None
Severe Nodulocystic acne and conglobate
acne
40–100* and fused >40* >10* Many
*Number of lesions on the face.
PRIMER
4
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
skin and in uninvolved skin of patients and may be
potential therapeutic targets83,87.
Propionibacterium acnes
The cutaneous microbiota might also be involved in
acne pathogenesis. A metagenomic analysis showed
that although the amount of Propionibacterium acnes on
the skin was similar between patients with acne (n = 49)
and healthy controls (n = 52), the strain populations
were different between the two groups. Certain P.acnes
strains were highly associated with acne, whereas other
strains were enriched on healthy skin88, which is impor-
tant given that different P.acnes strains have different
inflammatory potential. P.acnes typeIII is the most pro-
inflammatory strain and upregulates proteinase-
activated receptor2 (PAR2), TNF, matrix metalloprotein-
ase13 and tissue inhibitor of matrix metallo proteinase2
(REF.89). Certain P.acnes strains may be responsible for
infections that worsen acne lesions, an area that is being
further investigated90–93.
P.acnes and associated antigens (namely, lipo -
poly saccharides) upregulate the expression of pro-
inflammatory cytokines in cultured sebocytes90. P.acnes
induces IL-8 and TNF, whereas lipopolysaccharides
induce IL-8, TNF and IL-1α. Viable P.acnes (but not heat-
killed organisms) stimulate the release of IL-1β, IL-8 and
granulocyte–macrophage colony-stimulating factor94,95.
P.acnes also induces the expression of IL-17 in peripheral
blood mononuclear cells, and IL-17-positive cells are pre-
sent in the infiltrate around comedones96. P.acnes can pro-
mote TH17 and TH1 response pathways, which are activated
in acne lesions, by inducing the secretion of IL-17A and
IFNγ from CD4+ Tcells97. Furthermore, P.acnes triggers
NLRP3 (NOD-, LRR- and pyrin-containing3; also
known as NALP3) inflammasome activation in mono-
cytes, macrophages and sebocytes; this activation
depends on proteinases and reactive oxygen species
and results in IL-1β secretion80. Blocking NLRP3
expression blocks P.acnes-induced IL-1β secretion in
sebocytes98. Interactions between P.acnes and macro-
phages in the perifollicular dermis can induce IL-1β
and e xacerbate inflammation80.
Keratinocytes and sebocytes can recognize and be
activated by P.acnes via CD1, CD14 and TLRs99101.
TLR2 activation in keratinocytes and sebaceous glands
triggers the release of IL-1α invitro102. Bakry etal.103 have
documented differences in TLR2 expression between
acne-involved and normalskin.
Pilosebaceous glands express several antimicrobial
peptides (for example, psoriasin, β-defensins and catheli-
cidin), and the expression of these peptides is upregulated
in acne lesions104 and in the presence of P.acnes90,91. In
addition, MUFAs, such as palmitoleic acid and oleic acid,
which have antimicrobial activity against Gram-positive
bacteria99, and enzymes involved in their synthesis (for
example, stearoyl coenzymeA desaturase1 (SCD1))
are present in the sebaceous gland105. The TLR2 ligand
macrophage-activating lipopeptide2 stimulates both
SCD1 and fatty acid desaturase2 (FADS2) mRNA expres-
sion in SZ95 sebocytes100. Lauric acid, a free fatty acid pre-
sent in sebum, has strong antimicrobial activity invitro
against skin bacteria, including P.acnes. Topical applica-
tion or intradermal injection of lauric acid invivo led
to remarkable therapeutic effectiveness against P.acnes-
induced inflammation and a profound reduction in the
number of bacteria106. Furthermore, lauric acid, palmitic
acid and oleic acid — which are the typical free fatty acids
found in human sebum — enhanced the β-defensin2
expression and antimicrobial activity of human sebo-
cytes against P.acnes107. This finding indicates that sebum
free fatty acids are involved in the disinfecting activity of
human skin through their direct antimicrobial charac-
teristics and by inducing the expression of antimicrobial
peptides in human s ebocytes to enhance their innate
immune defence ability106.
Modern lifestyle, diet and smoking
The modern lifestyle, which includes diet, stress, urban
noise, socioeconomic pressure, light stimuli and vari-
ations in sleep patterns, is a potential risk factor for
acne35,108. Diet might contribute substrates for synthe-
sis of sebaceous lipids109, such as the essential fatty acid
linoleic acid. Low-glycaemic-load diets may reduce
sebum production via endocrine effects, whereas
a typical Western diet exacerbates acne42,110. Severe
caloric restriction curtails sebum excretion, which is
reversible by a normal diet111,112. Changes in dietary
fat or carbohydrate intake can also alter sebum pro-
duction and composition113. The apparent absence of
acne in native non-Westernized people in Papua New
Guinea and Paraguay also supports this notion114. Total
cholesterol, low-density lipoprotein (LDL) choles-
terol, high-density lipoprotein (HDL) cholesterol and
apolipoprotein A1 were higher in patients with severe
acne than in healthy, age-matched controls (n = 90);
however, the levels in patients were within the normal
range. Furthermore, lipid ratios for total cholesterol/
Nature Reviews | Disease Primers
Other skin and
subcutaneous diseases
Dental caries (baby teeth)
Dental caries
(permanent teeth)
Tension-type
headache
Migraine
Fungal skin diseases
Chronic
periodontitis
Mild hearing loss
Acne vulgaris
Low back pain
Figure 2 | The ten most prevalent diseases according to the Global Burden of
Disease study. Acne vulgaris was the eighth most prevalent disease globally in 2010,
whereas fungal skin diseases was fourth in global prevalence, and other skin and
subcutaneous diseases was in fifth place2. The category other skin and subcutaneous
diseases includes skin diseases (but excluding eczema, psoriasis, cellulitis, abscess,
impetigo and other bacterial diseases), scabies, fungal skin diseases, viral skin diseases,
acne vulgaris, alopecia areata, pruritus, urticaria and decubitus ulcer.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
5
© 2015 Macmillan Publishers Limited. All rights reserved
HDL, LDL/HDL, triglycerides/HDL, apolipoproteinB/
apolipoprotein A1, were all higher in patients with acne
than in controls, suggesting a possible dyslipidaemia in
patients with acne115. In addition, a lower body mass
index reduces the risk for acne lesions116,117.
The role of smoking in acne development is unclear.
Several studies have documented a positive correlation
between smoking, the number of cigarettes consumed
daily and acne development118, whereas other studies
showed no correlation or even a protective role of smok-
ing29,119. A potential mechanism by which smoking could
induce acne is by increasing oxidative stress that results
in a subsequent accumulation of lipid peroxide in come-
dones120 and an induction of phospholipaseA2-dependent
inflammation signalling cascades.
Certain drugs such as anti-epileptic agents and anti-
cancer drugs (for example, tyrosine kinase inhibitors)
may also produce a monomorphic acne and acneiform
eruptions (dermatoses that resemble acne vulgaris)26.
The use of anabolic drugs induces severe forms of
acne121. Dioxin exposure can result in severe comedonal
acne (chloracne)25.
Genetics
Genetics have a role in the development of acne, as
evidenced by family and twin studies22–24,122. Several
genetic polymorphisms affecting the expression and/or
function of genes have been investigated. Genes associ-
ated with acne included the IGF1 (CA)19 repeat poly-
morphism123, the Pro12Ala polymorphism of PPARG124,
the IL6-572 G/C polymorphism and the IL1A-889 C/T
polymorphism125; however, further studies in this field
are needed. In addition, two genome-wide studies in
Han Chinese populations have found acne susceptibility
loci (1q24.2 and 11p11.2)126. A study conducted in the
United Kingdom comparing severe cases of acne with
controls found three significant associations — 11q13.1
(rs478304; Pcombined = 3.23 × 10−11; odds ratio (OR):1.20),
5q11.2 (rs38055; Pcombined = 4.58 × 10−9; OR:1.17) and
1q41 (rs1159268; Pcombined = 4.08 × 10−8; OR:1.17) —
linked to the transforming growth factor-β cell signal-
ling pathway127. In addition, a genome-wide association
study of 928 Americans of European descent with severe
acne revealed that the single-nucleotide polymor-
phism rs4133274 on 8q24 (72-kb upstream of MYCN)
was significantly associated with severe teenage acne
(P = 1.7 × 10−6)128. Proteomic analysis of sebaceous fol-
licular casts extracted from 18healthy individuals and
20individuals with acne has also provided an overview
of acne pathogenesis and identified proteins involved in
inflammation, wound healing and tissue remodelling,
such as myeloperoxidase, lactotransferrin, neutrophil
elastase inhibitor and, surprisingly, vimentin in acne-
affected skin129. These data represent early results and
more evidence is required to fully unravel the genetic
background ofacne.
Diagnosis, screening and prevention
Clinical presentation and grading
Acne affects body areas characterized by an increased
density of pilosebaceous glands, such as the face, chest
and back130. The initial acne lesion is the micro comedone,
which is an invisible (to the naked eye) microscopic
structure. During the course of acne, non-inflammatory
lesions form, including closed (whiteheads) and open
(blackheads) comedones, followed by inflammatory
lesions that include superficial lesions such as papules
and pustules (≤5 mm in diameter) and deep pustules or
nodules130 (FIGS1,5).
Acne is diagnosed based on clinical examination
and can be classified according to severity, lesion type
and age of onset. Acne can be classified as mild, mod-
erate or severe and in accordance with the lesions that
predominate in a given patient: comedonal, papulo-
pustular, nodular, nodulocystic or conglobate acne
(acne conglobata)130 (TABLE1). Acne conglobata is a rare,
Nature Reviews | Disease Primers
Epithelial
hyperproliferation
Inflammation
Hyperseborrhoea
with pro-
inflammatory lipids
Propionibacterium
acnes
Bacterial antigens
Dietary lipids
Smoking
Genetic factors
Environmental factors
PPAR ligands
SREBP1
Regulatory
neuropeptides
Androgen excess
mTORC1
IGF1
Hair
Skin surface
Follicle
Sebaceous gland
Figure 3 | Tangled network of four core events in acne formation. Acne development depends on hyperseborrhoea,
epithelial hyperproliferation, Propionibacterium acnes activity within the follicle, and inflammation. Androgens, ligands of
peroxisome proliferator-activated receptors (PPARs), regulatory neuropeptides with hormonal and non-hormonal activity,
and environmental factors lead to hyperseborrhoea, epithelial hyperproliferation in the ductus seboglandularis and
acro-infundibulum and the expression of pro-inflammatory chemokines and cytokines, which stimulate the development
of comedones and inflammatory lesions. IGF1, insulin-like growth factor 1; mTORC1, mammalian target of rapamycin
complex1; SREBP1, sterol regulatory element-binding protein 1. Adapted with permission from REF.243, Wiley.
PRIMER
6
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
highly inflammatory, severe form of acne vulgaris, pre-
senting with grouped comedones, nodules, abscesses
and interconnected draining sinus tracts. This subtype
primarily affects adult males and manifests a chronic,
persistent course130. Furthermore, acne may be classified
on the basis of the age at presentation as neonatal acne
(<4weeks of age), infantile acne (3–16months of age),
mid-childhood (1–7years of age), prepubertal (7–9years
of age), adolescent (10–18years of age) or adult acne
(>25years of age, either continuing from puberty or new
late-onset acne)131133.
In clinical research studies, the assessment and grad-
ing of acne includes lesion counting, as well as overall
grading systems supplemented with photographic meth-
ods134. Acne lesion counting includes the numbers of
open and closed comedones, papules, pustules and nod-
ules on the face or trunk135. For the photographic method,
the photographs of the patients are compared with the
appropriate standard136. In all cases, adequate lighting is
important to avoid omitting non-inflammatory lesions.
Acne lesion counting should include the whole face (fore-
head, cheeks and chin) and not just a single facial area;
when appropriate, studies should include assessment of
acne lesions and progression in non-facial areas. Acne
lesion counting with recording of the lesions on a facial
template divided into five facial segments (including the
chin and the right and left forehead and cheek, excluding
the nose) is reliable137. Although stretching of the skin
facilitates the visualization of comedones, it is not per-
mitted for standard lesion counting because the degree
of stretching might vary135. The advantage of acne lesion
counting to grade acne is that individual lesions are pre-
cisely counted and classified as either non-inflammatory
or inflammatory lesions, which guarantees homogeneity
and facilitates comparison of different results of studies
on acne treatments134,135. To locate deep lesions, palpa-
tion is also necessary because they are not detected with
standard photographic methodology.
Acne grading systems have been proposed for use as
a complementary, easy to use and rapid mode of acne
grade assessment and for the selection of eligible patients
for therapeutic studies138,139. Overall scales might be less
quantitative but more relevant to clinicians and their
patients. Grading systems currently in use are listed
in BOX1. Currently, no overall acne grading system is
considered to be a global standard, although efforts are
underway to create a standard140,141.
Modern diagnostics through imaging
Various photographic methods have been proposed
over the years to visualize acne and grade its severity,
and to assess response to treatments134. Standard photo-
graphs are a useful and reliable tool but need to use
the same lighting, distance from the patient, camera
and processing procedures. Furthermore, photographs
are limited by the difficulty in distinguish deep lesions
from active superficial lesions and are less accurate for
non-inflammatory lesions134,135.
Modern imaging methods have provided new
opportunities for optimizing acne visualization and
improving the accuracy of the assessment of acne
severity and response to treatments142145. One study
has shown that autoclassification of acne lesions with
a multispectral and multimodal facial imaging system
have a strong correlation with results obtained by man-
ual counting of lesions (both inflammatory and non-
inflammatory lesions) by expert physicians (correlation
co-efficient of >0.9)144. Digital photography provides
various advantages, such as supervised or automatic
image analysis and ease of storage of large numbers
of photographs145. Advanced imaging techniques
include parallel polarization and orthogonal polari-
zation imaging, stereoimage optical topometer imag-
ing to construct three- dimensional stereoimages, and
fluorescence photography. Parallel polarization imaging
enhances the visualization of skin surface features, such
as papules, pore size, skin oiliness and acne scars145.
Orthogonal polarization (or cross-polarization) photo-
graphy enhances the visualization of inflammatory
acne lesions, erythema and skin brightness. Parallel-
polarized and cross-polarized photography with video
microscopy and sebum production measurement can
be combined. Fluorescence photography using short
wavelengths (long ultraviolet A or blue-range light)
can be used to visualize P.acnes density based on the
porphyrin production and the corresponding orange–
red fluorescence intensity. Multispectral images use
Fisher linear discriminant functions to classify acne
Nature Reviews | Disease Primers
Hormones
Neuropeptides
Sebocyte
Lipid
production
Differentiation
Proliferation
Inflammation
Chemoattractants
Propionibacterium
acnes
LPS
Lipoperoxides
MUFAs
TNF
Interleukins
β-defensin
Prostglandins
MMPs
Granulysin
Bacteriosides
Leukotrienes
EGFR
Perilipins
PPARγ
NF-κB
Sex steroids
IGF1
Testosterone
Estradiol
Progesterone
Cholesterol
DHEA
Glucocorticoids
Pregnenolone
Microbiota
Others
Pro-inflammatory cytokines, lipid mediators,
antimicrobial peptides and MUFAs
Substance P
CRH
α-MSH
VIP
Neuropeptide-γ
β-endorphin
Figure 4 | Pathophysiological processes involved in acne vulgaris. The
pathogenesis of acne involves several processes including sebum production, and
sebocyte differentiation, proliferation and inflammation. These processes are regulated
by circulating sex hormone levels as well as locally synthesized hormones,
neuropeptides, the microbiota and pro-inflammatory cytokines, lipid mediators,
antimicrobial peptides and monounsaturated fatty acids (MUFAs). α-MSH,
α-melanocyte-stimulating hormone; CRH, corticotropin-releasing hormone; DHEA,
dehydroepiandrosterone; EGFR, epidermal growth factor receptor; IGF1, insulin-like
growth factor 1; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; NF-κB, nuclear
factor-κB; PPARγ, peroxisome proliferator-activated receptor-γ; TNF, tumour necrosis
factor; VIP, vascular intestinal polypeptide.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
7
© 2015 Macmillan Publishers Limited. All rights reserved
and capture image data at specific wavelengths across
the electromagnetic spectrum136,145.
Differentiation from other dermatological conditions
Acne is clinically heterogeneous and differential diag-
nosis is based on the type of lesion, age at disease onset
and persistence of acne in adulthood. The differential
diagnosis is usually possible on clinical grounds and the
patient’s medical history; however, when in doubt, labo-
ratory tests, imaging or histopathological examination of
a skin biopsy may need to be performed to exclude other
conditions to establish a correct diag nosis146 (TABLE2). In
all cases, the presence of comedones is a prerequisite for
establishing diagnosis ofacne147.
On the basis of the age of presentation, neonatal acne
should be differentiated from skin infections (bacterial,
viral or fungal), transient benign pustular eruptions
(neonatal cephalic pustulosis, erythema toxicum neo-
natorum and transient neonatal pustular melanosis),
milia, sebaceous gland hyperplasia, miliaria, infantile
acne, acne induced by topical oils and ointments (acne
venenata infantum), drug-induced acneiform eruptions
and congenital adrenal hyperplasia19. The differential
diagnosis of childhood acne includes perioral dermati-
tis and childhood rosacea146. More complex conditions
that may need to be differentiated from acne vulgaris
include the synovitis acne pustulosis hyperostosis osteitis
(SAPHO) syndrome, and pyogenic arthritis, pyoderma
gangrenosum and acne (PAPA) syndrome19,148.
Prevention
The prevention of acne relies on the successful manage-
ment of modifiable risk factors implicated in its devel-
opment, including underlying systemic diseases and
lifestyle factors. Acne may be the cutaneous manifesta-
tion of an underlying systemic disease such as congeni-
tal adrenal hyperplasia or polycystic ovary syndrome;
in these cases, the timely and successful management of
the underlying disease will prevent the presentation or
persistence of acne19,148.
Various lifestyle factors, such as dietary habits,
ob esity and smoking, may influence the development
of acne149. However, the effect of lifestyle interventions
on acne remains a largely debated issue, as epidemio-
logical studies have produced contradictory results, and
well-designed trials that are able to produce evidence-
based results are largely lacking. A case–control study
that investigated the association of dietary habits in
people with acne (n = 205) and without acne (n = 358)
reported an increased risk of acne development only
with the increased consumption of milk (in particular,
skimmed milk) but not with the consumption of cheese
or chocolate117. Similarly, self-reported history of acne
was positively associated with intake of skimmed milk
in a prospective cohort study of 4,273 boys. Milk might
influence comedogenesis through hormonal pathways,
as milk contains androgens (precursors of dihydro-
testosterone and other non-steroidal growth factors),
or through higher levels of IGF1, which might affect
the pilosebaceous unit150. A community-based study
of high school pupils in Tehran, Iran (n = 933) reported
that the regular consumption of sweets, nuts, chocolates
and oily foods was associated with increased acne sever-
ity5. A cross-sectional study in 1,871 patients with acne
reported that frequent fat and sugar intake were associ-
ated with increased risk of acne151. However, other stud-
ies have failed to show an association between diet and
acne152. Considering these controversies, more studies
are warranted.
Very few randomized controlled studies have been
conducted to assess the role of dietary interventions
on acne. A low-glycaemic-load diet for 12weeks was
associated with a greater reduction in the total number
of acne lesions compared with the patients on a conven-
tional high-glycaemic-load diet (−21.9 (95%CI: 26.8 to
−19.0) versus −13.8 (95%CI: −19.1 to −8.5); P = 0.01)
in one small trial (n = 43; all participants had acne and
were male). The low-glycaemic-load diet was also asso-
ciated with weight reduction, decreased free androgen
index, increased IGF-binding protein 1 (IGFBP1) levels
(mean increase in log(IGFBP1): 0.14 ng per ml) and
improved insulin sensitivity153. Similar results were
obtained in a small number of patients (n = 17) when
the low-glycaemic-load diet was given for 10weeks154.
Another randomized, blind, controlled study showed
that omega-3 fatty acids or γ-linolenic acid (a omega-6
fatty acid) supplementation for 10weeks in 45 patients
with acne resulted in a significant improvement in the
acne severity grade and in inflammatory acne lesion
counts155. Omega-3 fatty acids may reduce inflamma-
tion by inhibiting pro-inflammatory cytokines, and
Nature Reviews | Disease Primers
Figure 5 | Clinical presentation of acne vulgaris. Acne
lesions, including comedones (white arrows), papule
(yellow arrow) and pustule (black arrow) on the facial skin.
PRIMER
8
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
γ-linolenic acid can have anti-inflammatory actions
via inhibition of leuko trieneB4 (REF.155). Finally, a
case–control study reported that individuals with
a body mass index of >18.5 had an increased risk of
acne117. Obesity may be accompanied by peripheral
hyperandrogenism, which may be associated with
increased sebum production and the development
of acne117. No association was found between smok-
ing and acne in this study, but another study has
shown a correlation between smoking and comedonal
post-adolescentacne156.
Management
A large number of acne treatment products are available,
and a wide range of combination products have been
introduced, which offer numerous treatment options
to various patients with different preferences. However,
large, well-designed, randomized controlled trials to
assess and compare the effectiveness of acne treatment
options are either lacking or have used different designs
and methodologies, resulting in a scarcity of strong evi-
dence to support many of the recommendations in acne
treatment guidelines. Hence, current guidelines rely on
the opinions of experts. Furthermore, for acne associated
with systemic diseases, therapeutic information is mostly
at the level of case reports19,148.
Current guidelines for acne treatment include
those from the Global Alliance to Improve Outcomes
in Acne6,157, the American Academy of Dermatology/
American Academy of Dermatology Association158, the
European Dermatology Forum Evidence-based (S3)
guidelines for the treatment of acne159, the European
expert group on oral antibiotics in acne160, and the Forum
for the Improvement of Clinical Trials in Acne position
on isotretinoin161. Some general principles that form
the foundation of these guidelines are as follows. Acne
is no longer considered a natural part of the life cycle,
and to prevent its psychological and physical sequelae,
early and aggressive treatment is necessary. Longitudinal
studies of the natural history of acne focusing on the
role of early treatment in preventing persistent disease
are yet to be conducted162. As a multifactorial disease,
combination therapy seems to be the most reasonable
approach in most cases6. Guideline recommendations
are categorized according to acne severity and the pres-
ence or absence of inflammation (TABLE3). Combination
of a topical retinoid plus an antimicrobial agent is rec-
ommended as first-line therapy for most patients with
acne, targeting multiple pathological factors in both
inflammatory and non-inflammatory acne lesions. Two
key exceptions for this general rule are severe acne and
mild comedogenic or non-inflammatory acne. For mild
comedogenic or non-inflammatory acne, treatment usu-
ally starts solely with a topical retinoid, whereas in the
case of severe acne, oral isotretinoin therapy should be
considered early. To limit antibiotic resistance, antibiotic
monotherapy should be avoided. In mild-to-moderate
acne, topical anti biotics should be used with benzoyl
peroxide (BPO) and a topical retinoid, and oral anti-
biotics are better reserved for moderate-to-moderately
severe acne; the duration of antibiotic use should be lim-
ited163. Isotretinoin remains the treatment of choice for
severe acne, but several precautionary measures have to
be taken during an isotretinoin course149,161.
Topical retinoids
Topical retinoids are vitaminA derivatives. The bind-
ing of retinoids to their receptors — the retinoic acid
receptors and the retinoid X receptors — in keratino-
cytes reduces follicular hyperkeratinization and decreases
adhesion164. This effect not only results in inhibition of
comedogenesis but also might enhance the penetra-
tion of other topical acne medications. Furthermore,
Box 1 | Commonly used acne grading scales
Leeds grading technique*
0.25–1: physiological acne
1.5–10: clinical acne
Revised Leeds grading technique
1–3: non-inflamed acne on the face
1–12: acne on the face
1–8: acne on the chest
1–8: acne on the back
Plewig and Kligman numerical grading of comedonal acne§
I: <10 comedones
II: 10–25 comedones
III: 25–50 comedones
IV: >50 comedones
Plewig and Kligman numerical grading of papulopustular acne§
I: <10 inflammatory lesions
II: 10–20 inflammatory lesions
III: 20–30 inflammatory lesions
IV: >30 inflammatory lesions
Global Evaluation Acne scale||
0: no acne lesions; residual pigmentation and erythema may be seen
1: almost no lesions, with a few scattered open or closed comedones and very few
papules
2: mild acne, in which <50% of the face is involved with a few comedones, papules
and pustules
3: moderate acne, in which >50% of the face is involved with many papules, pustules,
comedones and a maximum of one nodule
4: severe acne, in which the entire face is involved, covered with many papules,
pustules, comedones and rare nodules
5: Very severe acne with highly inflammatory lesions covering the whole face with the
presence of nodules
US FDA’s Investigator’s Global Assessment for acne vulgaris
0: no acne lesions
1: almost clear skin with rare non-inflammatory lesions and no more than one papule
2: mild acne with some non-inflammatory lesions and no more than a few papules or
pustules
3: moderate acne with many non-inflammatory lesions, some inflammatory lesions,
and no more than one nodule
4: severe acne with many non-inflammatory lesions and inflammatory lesions, but no
more than a few nodular lesions
*Overall assessment of acne severity in different body areas (face, back and chest) based on
reference greyscale facial photographs135. Revision of the Leeds grading to include reference
colour photographs and the introduction of grade 1–3 for non-inflammatory acne139. §On one
side of the face. ||In Europe240. In the United States241.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
9
© 2015 Macmillan Publishers Limited. All rights reserved
retinoids have anti-inflammatory effects by inhibiting
the activation of the transcription factor AP1 (REF.165),
and by downregulating the expression of TLR2 (REF.166).
Owing to these comedolytic (that is, agents that break
up com edones and open up clogged pores) and anti-
inflammatory effects, topical retinoids are strongly
recommended in the treatment regimen of both com-
edogenic and inflammatory acne as an initial and
maintenance treatment and to avoid relapses6. Topical
retinoids for the treatment of acne include tretinoin,
adapalene, tazarotene (which is not available in Europe),
retinaldehyde and topical isotretinoin (the latter two are
not available in the United States), which are all available
in various formulations and concentrations167. To pre-
vent acne development or maintain improvement and
avoid acne relapses, the application of appropriate topical
treatment is recommended159. The fact that the micro-
comedone is the initial microscopic acne lesion high-
lights the need for applying topical acne therapies not
only on clinically apparent lesions but also on the whole
face to prevent the development of visible lesions159.
However, because they should be applied to the whole
affected area, topical treatments often cause irritation
and dryness. In addition, use of topical retinoids is not
recommended during pregnancy; tazarotene is classi-
fied as a pregnancy category X drug (that is, fetal risk
has been proven in investigational or marketing studies
in humans) and is contraindicated, whereas adapalene
and topical tretinoin are classified as pregnancy cat-
egory C drugs (that is, adverse effects have been shown
in animal studies, but controlled studies in humans are
still lacking). Several randomized trials have compared
different topical retinoids, but more studies are needed.
Adapalene products tend to be the most tolerable of treat-
ments. Topical retinoids are also reasonable choices for
ma intenance therapy after initial successful treatment.
Topical antimicrobials
BPO. BPO, an organic peroxide derived from a by-
product of coal tar, has become the most widely used
topical acne medication in dermatology168. BPO treat-
ment alone improves inflammatory acne157, and its
mechanisms of action include antimicrobial, anti-
inflammatory and keratolytic effects and wound-healing
activity168. Although more potent than any prescription
antibiotic against P.acnes, BPO remains safe for human
use168. Low-strength (2.5% or 5%) BPO is recommended,
as it is less irritating than and as effective as higher
concentration preparations169.
For BPO, as with adapalene, the time to achieve a
25% reduction in the mean number of inflammatory
lesions does not change for different concentrations in
patients with mild-to-moderate papulopustular acne.
However, BPO seemed to act faster than topical ada-
palene, tretinoin and isotretinoin170. Some authors have
suggested starting treatment with BPO alone for mild
inflammatory acne, owing to the cost of retinoids, safety
and good results162. BPO is also available as a fixed-dose
combination product with adapalene that can help to
reduce the complexity of treatment.
Topical antibiotics. Erythromycin and clindamycin are
the most commonly used topical antibiotics in acne
treatment, both of which are available in different for-
mulations. Antibiotics (either topical or oral) are not
intended to be a monotherapy for acne. For example,
Table 2 | Differential diagnosis of acne vulgaris
Condition Patient history Clinical presentation Diagnostic methods
Laboratory test Skin biopsy Imaging
Drug-induced
acneiform
eruptions
History of drug intake, including
halogenated compounds (iodides,
radiopaque contrast materials and
bromides), anti-epileptic drugs
(phenytoin and carbamazepine),
antidepressant drugs (lithium),
anti-tubercular drugs (isoniazid),
growth hormone, cyclosporine,
vitamins (B1, B6 and B12) and EGFR
inhibitors
Monomorphous papules
or pustules; localization
on the trunk and upper
extremities
N/A Degeneration of the
follicular epithelium, with a
localized intrafollicular and
perifollicular neutrophilic
inflammatory reaction
N/A
Papulopustular
rosacea
More common in women
30–40years of age; chronic course
No comedones; mild
flushing or erythema at the
convexities of the face
N/A Not diagnostic N/A
Gram-negative
folliculitis
Long-term oral antibiotic treatment
for acne
Papules and pustules Bacterial culture
and Gram
staining
Infiltrate of inflammatory
cells (mainly neutrophils,
later mixed with
lymphocytes) in the
follicular ostium and upper
regions of the follicle
N/A
Acne
fulminans
Affects adolescent boys; can be
precipitated by oral isotretinoin
intake
Sudden onset of
haemorrhagic ulcerative
acne mainly on the trunk;
fever, myalgias and
arthralgias
Anaemia or
leukocytosis
Haemorrhagic epidermal
necrosis and granulocytes
in the dermis
Focal lytic
bone lesions
or sacroiliitis
might be
present
EGFR, epidermal growth factor receptor; N/A, not applicable.
PRIMER
10
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
topical antibiotics should only be used in combination
with BPO to help prevent the development of antibiotic-
resistant bacteria. Fixed-dose combination gels of topi-
cal antibiotics with BPO are also available171, as well as
a combined gel formulation of clindamycin with treti-
noin172,173. The clindamycin and BPO combination seems
to act more rapidly than adapalene; this combination
might be faster than BPO alone, but more studies are
needed to confirm this result170. A combination of ada-
palene and BPO and that of clindamycin and BPO have
comparable times to achieve a 25% reduction in lesion
count170,171. Dapsone gel is a newer topical antibiotic
choice. Although the mechanism of action of dapson is
not yet clear, it has shown good results in studies and
various new options are in development174.
Other topical agents
Salicylic acid is a topical medication present in many
over-the-counter products, which has comedolytic
effects but may be less effective than retinoids. Another
topical agent, azelaic acid, has antibacterial, comedo-
lytic and anti-inflammatory properties and is consid-
ered as a potential first-line monotherapy for female
adult patients with acne, and a good choice for main-
tenance therapy owing to its good tolerability and
safety175. Apotential adverse effect of azelaic acid is
hypopigmentation, which might be helpful in treat-
ing post-inflammatory hyperpigmentation. Although
most publications have investigated the 20% azelaic
acid cream formulation, the 15% gel was as efficient as
BPO and topical clindamycin for patients with mild-to-
moderate acne176. A novel study using the cyano acrylate
technique — a precise method for microcomedone
assessment — in patients with mild-to-moderate acne
has shown an equivalent effect for azelaic acid 15% gel
compared with 0.1% adapalene177.
Oral antibiotics
Doxycycline and minocycline have replaced tetra-
cycline and erythromycin in most cases of acne therapy.
Tetracycline, doxycycline and minocycline are contra-
indicated in pregnancy and in children <9years of age;
erythromycin is only recommended in these cases.
Azithromycin is not commonly used owing to the risk of
increasing resistance, which is a crucial issue in other dis-
eases. As tetracyclines control acne through their direct
anti-inflammatory effects in addition to their antibiotic
property, using subantimicrobial doses of doxycycline is
promising, but more investigation is needed in this field.
Although minocycline is effective in acne treatment, its
superiority to other tetracyclines has not been proven178.
Extended-release minocycline has shown good results
in acne treatment179, and co-trimoxazole is an alterna-
tive for severe acne. Several studies have compared the
efficacy of different antibiotics in acne therapy, but no
antibiotic demonstrated superior results.
To reduce the development of antibiotic resistance,
systemic antibiotic therapy should always be combined
with a topical retinoid or BPO and should be limited to a
period of 3months180; 4–6weeks after the start of treat-
ment is the appropriate time for response assessment160.
Concomitant treatment of oral and topical antibiotics, and
use of topical antibiotics without BPO should beavoided6.
However, an analysis of published data of 29,908 patients
from 2008 to 2010 demonstrated that the mean duration
of oral antibiotic therapy was 129days — much longer
than indicated. Simultaneous topical retinoid therapy did
not occur in 57.8% of treatment courses181. There has been
a shift towards non-antibiotic treatment in acne manage-
ment182, but there is still the need to inform all physicians
about the importance of short (<3months) regimens in
different settings. A study of patients with preadolescent
acne found that dermatologists predominantly prescribe
topical retinoids for this age group, whereas primary care
physicians prescribe antibiotics, particularly oral anti-
biotics183. That is, primary care doctors are not familiar
with using adapalene in teenagers.
Hormonal therapy
Hormonal agents that reduce androgen activity can be
given to reduce sebum production in women. Oral con-
traceptives and, in some countries, spironolactone are
commonly prescribed hormonal therapies. The use of
anti-androgen treatment is not limited to acne induced
by hyperandrogenism; this therapy also improves acne in
women with normal serum androgen levels157. Hormonal
therapy can be prescribed in combination with other
acne medications for postmenarcheal to premenopausal
women with moderate-to-severe acne who do not intend
to become pregnant. In addition, they will improve even
mild acne in patients who use this medication for con-
traception, menstrual cycle irregularities or patients who
experience cyclical acne flares184. Hormonal therapy may
be underused in women with acne185.
It takes 6–12months before one can evaluate hormo-
nal therapy results186. Meta-analyses of previous publi-
cations demonstrated that, although antibiotics might
be superior at 3months, oral hormonal anti-androgens
are equivalent to antibiotics at 6months in reducing
acne lesions and, therefore, could be a better first-line
alternative to systemic antibiotics for long-term acne
management in women186,187. There are multiple oral
hormonal anti-androgens on the market; patient pref-
erence, cost and adverse-effect profile should determine
the a ppropriate choice185.
Spironolactone, which has been long used in
treating women with acne and hirsutism, is not US
FDA approved for these disorders. Indeed, a study in
Cochrane Database of Systematic Reviews did not find
sufficient evidence to confirm spironolactone as effi-
cacious in acne or hirsutism187. Debate on the efficacy
of this medication, and the appropriate dosing, in the
medical literature still continues. Thus, spironolactone
therapy could be started for women with moderate-
to-severe acne who fail to respond to combinational
treatment regimens (TABLE3), before considering oral
isotretinoin therapy.
Although hormonal therapy for acne has long been
limited to systemic treatment in women, it seems that
topical anti-androgens are emerging; spironolactone
5% gel and cortexolone 17α-propionate 1% cream are
awaiting FDA approval for use in men and women188.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
11
© 2015 Macmillan Publishers Limited. All rights reserved
Oral isotretinoin
Oral isotretinoin has effects on all four pathophysiologi-
cal pathways of acne and can have a permanent effect
on the disease course. With a 90% reduction in sebum
production189 and almost 85% cure rate (that is, resolu-
tion without relapse)190, isotretinoin is a highly effective
drug to treat acne, but not a ‘miracle’ for every patient191.
The effects of isotretinoin on sebum production might be
explained by cell cycle arrest or apoptosis188. Isotretinoin
influences the G1–S phase of the cell cycle by decreasing
DNA synthesis, increasing p21 (encoded by CDKN1A)
protein expression and decreasing cyclin D1 protein
expression188 — effects that are independent of retinoic
acid receptor activation. Isotretinoin also induces apop-
tosis in sebocytes. Reduced sebum production induced
by isotretinoin treatment may be the result of sebaceous
gland involution188. Oral isotretinoin is the treatment of
choice for severe, recalcitrant, nodular acne and may also
be started for patients with scarringacne.
Isotretinoin can cause numerous adverse effects, but
severe effects are rare161,186,192. Although uncommon,
depression is among one of the adverse effects and should
be monitored193. Owing to teratogenicity, physicians in
the United States should prescribe isotretinoin through
the iPLEDGE system, which is a risk evaluation mitiga-
tion strategy designed to prevent the use of isotretinoin
during pregnancy. Although isotretinoin may cause
severe birth defects, estimating the expected risk using
quality-adjusted life years (QALYs) shows that the QALY
benefit of treating patients with severe, moderate and
mild acne is 50-, 11- and 7-times greater, respectively,
than the risk of QALY loss from isotretinoin teratogeni-
city194. A micronized formulation of oral isotretinoin
(isotretinoin-lidose) with improved bioavailability and
better intestinal absorption helps to maintain stable lev-
els of isotretinoin in the plasma and carry a lower risk
of mucocutaneous events and hypertriglycaeridaemia195.
Oral isotretinoin treatment is a common reason for
patients with acne to visit dermatology departments
for support; it seems necessary to provide adequate
information when prescribing196. In addition, there may
be racial and sex differences in the use of oral isotreti-
noin for acne management in the United States, with
black and female patients being less likely to receive oral
iso tretinoin therapy197.
Adjunctive therapies
Comedone extraction might help to relieve resist-
ant comedones but should be used in conjunc-
tion with conventional therapeutic medications157.
Microdermabrasion, a technique that uses minute crys-
tals to exfoliate the skin, does not have sufficient medical
literature support to be considered effective in the man-
agement of acne, and future studies are needed6,158. The
same is true for chemical peeling with glycolic acid (an
α-hydroxy acid) or salicylic acid (a β-hydroxy acid)157,158.
Although clinical experience shows that intralesional
steroid injection is effective in treating nodular acne,
structured studies are needed to determine the appropri-
ate dosage158. Probable adverse effects of steroids should
Table 3 | Summary of therapeutic recommendations*,‡
Recommendation Comedonal
acne
Mild-to-moderate papulopustular acne Severe papulopustular
acne or moderate
nodular acne
Severe nodular or
conglobate acne§
High-strength
recommendations
None Adapalene plus BPO (f.c.)
BPO plus clindamycin (f.c.)
Isotretinoin* Isotretinoin*
Medium-strength
recommendation
Topical
retinoid||
Azelaic
acid
BPO
Topical retinoid||
Systemic antibiotic plus adapalene
Systemic antibiotics# plus
adapalene
Systemic antibiotics# plus
azelaic acid**
Systemic antibiotics plus
adapalene plus BPO (f.c.)
Systemic antibiotics# plus
azelaic acid
Low-strength
recommendation
Azelaic
acid
BPO
Blue light
Oral zinc
Topical erythromycin plus isotretinoin (f.c.)
Topical erythromycin plus tretinoin (f.c.)
Systemic antibiotic‡,# plus BPO‡‡
Systemic antibiotic‡,# plus azelaic acid
Systemic antibiotic‡,# plus adapalene plus BPO
(f.c.)§§
Systemic antibiotics# plus
BPO‡‡
Systemic antibiotics#
plus BPO‡‡
Systemic antibiotics#
plus adapalene§§,¶
Systemic antibiotics#
plus adapalene plus BPO
(f.c.)§§
Alternatives for
female patients
None None Hormonal anti-androgens
plus topical treatment
Hormonal anti-androgens
plus systemic antibiotics||||
Hormonal anti-androgens
plus systemic antibiotics||||
BPO, benzoyl peroxide; f.c., fixed-dose combination. *Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation
as a first-line therapy (for example, financial resources or reimbursement limitations, legal restrictions, availability and drug licensing). In case of more widespread
disease or moderate severity, initiation of a systemic treatment can be recommended. §Systemic treatment with corticosteroids can be considered. ||Adapalene to
be preferred over tretinoin or isotretinoin. Only studies found on systemic antibiotics plus adapalene, isotretinoin and tretinoin can be considered for
combination treatment based on expert opinion. #Doxycycline and lymecycline. **Indirect evidence from nodular and conglobate acne and expert opinion.
‡‡Indirect evidence from a study also including chorhexidin, recommendation additionally based on expert opinion. §§Indirect evidence from severe
papularpustular acne. ||||Low strength of recommendation. Adapted with permission from REF.159, Wiley.
PRIMER
12
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
also be considered before starting therapy. Systemic ster-
oids can be administered as primary therapy together
with isotretinoin in severe acne cases with systemic signs
(acne fulminans)186.
Light therapy
Light therapy methods include broad-spectrum con-
tinuous-wave visible light sources (such as blue light
or red light), intense pulsed light, laser sources (such
as potassium titanyl phosphate lasers, pulsed dye lasers
and infrared lasers) and photodynamic therapy. These
modalities work through inhibition of P.acnes and/or
thermal damage to the sebaceous glands198.
Photodynamic therapy consists of application of a
photosensitizing agent, most commonly aminolevulinic
acid, or methyl aminolevulinic acid, followed by expo-
sure to blue or red light, lasers, pulsed light sources or
non-pulsed broad-spectrum light. Although photo-
dynamic therapy has been extensively studied in acne,
there is no consensus on a protocol. The use of low-dose
photodynamic therapy characterized by lower drug
concentrations, low-light doses and less-penetrating
blue light results in short-term effects probably through
antimicrobial or immunomodulatory effects. By contrast,
high-dose photodynamic therapy results in prolonged
effects owing to destruction of sebaceous glands198,199.
Aminolevulinic acid followed by red light — which
penetrates more deeply into the skin and has effects on
non-inflammatory lesions in addition to inflammatory
lesions — seems to be the optimal choice200. The common
adverse effects of photodynamic therapy are tolerable and
transient, but caution is warranted when treating patients
with dark skin owing to post-inflammatory pigmentary
changes201. Light therapies alone are not highly effective,
although red–blue light was more effective than topical
5% BPO cream in the short term (4weeks to 1year)202.
Most photodynamic therapy trials have shown ben-
efit, especially with multiple treatment sessions202 and
for non-inflammatory acne lesions. However, even for
inflammatory acne lesions, photodynamic therapy was
less effective and less tolerable than topical 1% adapalene
gel202. Thus, although there has been progress in this field,
more evidence is needed to define the efficacy of light
therapies. Currently, they are considered as an adjunct
to medical therapies or for patients who do not desire
medicaltreatments6.
Adherence to treatment
Adherence to acne treatment is poor, as evidenced by
studies using indirect assessment tools as well as objective
electronic monitoring. For objective electronic monitor-
ing, adherence of typical patients (teenagers with acne
receiving topical BPO), who were not informed that they
were part of a clinical trial, decreased from 82% on day 1
to 45% at day43 (P < 0.001)203.
Adherence to acne medications is important for treat-
ment efficacy, and seems to be an important component
of better health status, and pharmacological treatment of
acne does not add significantly to acne-related annual
health care costs (for the patient and the health care
system)204. Several predictors for adherence have been
identified; with older age, married status, female sex,
out-of-pocket cost, oral isotretinoin, gel formulations,
once-daily formulations and convenient formulations
being positive predictors, whereas smoking, drinking
alcohol, unemployment and psychiatric morbidity are
negative predictors8. Good physician–patient relation-
ships, education about the pathophysiology of acne and
considering the patient’s preference for the topical deliv-
ery vehicle can improve adherence. More frequent visits
to the physician increases adherence, and is superior to
a standard visiting schedule and daily reminder phone
calls to patients and parents205,206.
Evaluation of the psychiatric morbidity, especially
anxiety and depression, may be beneficial. Most topi-
cal acne treatment products cause irritation; informing
patients of possible adverse effects, providing written
instruction on how to manage irritation and dryness
and considering alternative treatments are helpful
strategies in this case207. A helpful factor in adherence
improvement is the use of fixed-dose combination prod-
ucts208,209. Several antibiotics and BPO combinations
are available, and an adapalene and BPO combination
adheres to both the BPO and the retinoid guidelines6.
Although fixed-dose combination topical formulations
might be part of a safer and more cost-effective alter-
native model to oral isotretinoin for treating severe
acne, the high adherence of isotretinoin treatment is
important to keep in mind. In a retrospective cohort
study of 24,438 patients from 2004 to 2007 using the
Marketscan Medicaid Database, a US national health
care claims database, adherence was measured among
different acne drug classes using the medication posses-
sion ratio (MPR). Patients were most adherent to oral
retinoids than any other acne drug classes (MPR: 0.78;
57% adherent) and the least adherent to oral antibiotics
(MPR: 0.21) and topical retinoids (MPR: 0.31)210.
Acne scars
Scars are important permanent sequelae of acne211,212.
Up to 95% of patients with acne have scars, with 30%
developing severe scars213. None of the currently avail-
able treatments achieve complete resolution of scars.
Prevention of scars by early and aggressive acne treat-
ment remains the best option. There are numerous
medical, surgical and procedural options that can help
to achieve profound cosmetic improvement in acne
scars. Using these methods in combination can even be
more successful6,214. There are two main types of acne
scars depending on the tissue response to inflammation:
scars caused by increased tissue formation (hypertrophic
and keloidal scars) and scars caused by loss of tissue
(atrophic scars). Atrophic acne scars are more com-
mon than keloids and hypertrophic scars, and can be
divided into three subtypes: icepick or V-shaped, rolling
or M-shaped and boxcar or U-shaped. Keloidal scars are
more common in darker-skinned individuals215.
Some scar treatments might be focused on a single
scar, such as surgical techniques including excision,
punch elevation, and subcision, debulking, skin graft or
dermal fillers. Other treatment options might be applied
to the entire affected area, including chemical peels,
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
13
© 2015 Macmillan Publishers Limited. All rights reserved
laser therapy or dermabrasion. With the advent of laser
resurfacing, dermabrasion is now used less frequently.
Topical retinoids used with procedures improve results
and reduce the risk of changes in pigmentation6. Silicone
dressings focus on hypertrophic scars and are less effec-
tive in keloids216. Intralesional corticosteroids and cryo-
surgery are the most effective regimens in the treatment
of hypertrophic scars and keloids214,215.
Quality of life
The WHO defines quality of life as the individual’s per-
ception of the position in life in the context of the culture
and value systems in which someone lives and in rela-
tion to his or her goals, expectations, standards and con-
cerns. Acne lesions modify the individual’s perception
and affect every aspect of personal, social, vocational
and academic life 217. Patients with severe acne (FIG.6)
have higher un employment rates than those without
acne218. Acne has a profound impact on a patients emo-
tions (self- embarrassment, self-esteem and feelings of
unworthiness), annoyance owing to physical symptoms
(pain and itch) and daily discomfort owing to treat-
ment219,220. Patients with acne usually experience social
anxiety and shame; they avoid eye contact, grow their
hair long to cover the face, use makeup and choose a
specific clothing style to minimize the appearance of
acne lesions219,221,222. Patients with acne reported social,
psychological and emotional problems that were as great
as those reported by patients with asthma, epilepsy,
diabetes, back pain or arthritis223.
Acne is associated with an increased risk of depres-
sion, anxiety and body dissatisfaction211. Depression is
2–3-times more prevalent in patients with acne than in
the general population, and the rate of depression was
twice as high in women with acne than in men224,225.
Patients with mild-to-moderate acne even exhibit
higher depression scores than patients with alopecia
areata, atopic dermatitis or psoriasis. Although acne
might be more psychologically damaging to adolescents
than adults, a higher prevalence of depression in older
patients with acne has been observed226. Suicidal idea-
tion rates were higher among patients with acne than
patients with general medical conditions226. Acne is
frequently associated with scarring, which continues to
affect psychopathological well-being in later life227.
Acne alone may be a source of stress and anxiety, but
stress can also trigger or exacerbate acne even after con-
trolling for changes in diet and sleep habits; a vicious
cycle can occur. Neuroimmunological research may pro-
vide the first insight into the links between acne stress
and quality of life228,229.
The most frequent lesions associated with greater
impairment are cysts and nodules; even those who
have only comedones report symptoms (itch and pain)
and emotional effects (decreased self-esteem, diffi-
culties in building relationships and social activities).
However, the effect of acne on quality of life does not
always correlate with acne severity. For this reason, rec-
ognition of clinical and pertinent psychological signs
must be taken into account when individualizing treat-
ment. Importantly, effective acne therapy significantly
improves quality of life230,231.
Outlook
Although acne is a very common and costly disease,
it does not receive the attention it deserves. Acne was
among the under-represented diseases in Cochrane
Database of Systematic Reviews when matched with cor-
responding diseases with a similar burden defined by
disability-adjusted life years from the Global Burden of
Disease 2010 project1,232–234. Another study showed that
although acne caused the fourth greatest skin-related dis-
ability in the United States, it received less than half of the
funding that was given by National Institute of Arthritis
and Musculoskeletal and Skin Diseases to projectson
bacterial skin diseases, which only rank thirteenth
on the disability score235. To advance the understanding
and treatment of acne, one first needs to acknowledge
that it is an important problem.
Basic research is needed to define pathways and regu-
latory nodes that can potentially be targeted to prevent
and treat acne and requires a multidisciplinary approach,
including microbiology, endocrinology, immunology,
genetics and dermatology31,87. On the basis of the results
obtained from these research projects, new therapeutic
agents have been developed or are under development75,236.
Formulation of consensus guidelines requires large, well-
designed, comparative, randomized controlled trials.
Development of a standardized, objective acne grading sys-
tem is a key factor needed for evaluating the results of clini-
cal studies, for facilitating comparison of results of different
studies and for developing clinical guidelines145. Basic sci-
ence can provide clues for the development of a reason-
able grading system. Large-scale longitudinal studies are
also necessary to observe the lifelong behavioural nature of
this disease in a population in depth. Current research pro-
vides a complex network of data, which is shallow in many
Nature Reviews | Disease Primers
Figure 6 | Acne conglobata. A male patient with acne conglobata on the face,
presenting with grouped comedones, highly inflammatory nodules and
interconnectedsinus tracts.
PRIMER
14
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
areas and does not offer a strong foundation for further
advancement with an acceptablespeed.
Acne management requires a combination treat-
ment approach, and the resulting complexity reduces
adherence. A theoretically effective therapeutic regimen
will not achieve its full potential when adherence is low.
Isotretinoin is an example of a single drug with the ability
to permanently suppress all the pathophysiological routes
and is associated with good adherence, but teratogenic-
ity risk and adverse effects limit its use. P.acnes develops
resistance to antibiotics, therefore, new antibiotics may
not be helpful as monotherapy, at least not for long. By
contrast, non-antibiotic, anti-inflammatory systemic
treatments are required237,238. Topical medications alone
will not be sufficient to control severe acne. Systemic anti-
androgens cannot be prescribed in men, and they are not
always as effective in women and do not offer a perma-
nent cure. Phototherapy methods might be promising but
are costly because they require intensive involvement of a
medical expert during therapeutic sessions. The finding
that laser wavelengths of 1,720 nm selectively target seba-
ceous glands239 has brought hope to establish a procedural
acne therapy with permanent effects that could replace the
need to rely on a teratogenic drug, such as isotretinoin.
Vaccines, treatments targeting different pathogenetic
factors, together with reformulations of available medi-
cations to improve absorption and reduce irritation are
different efforts in hope of better treatment options. Anti-
inflammatory agents may be good candidates for acne
therapy, and defining specific targets might limit adverse
effects. Future studies will continue to search for a safe
multipotential permanent cure for acne (TABLE4).
Table 4 | Novel agents for acne treatment
Category Drugs, comments Refs
Galenic formulations of
existing retinoids
Tretinoin in tocopheryl vesicles 244
Gel containing adapalene-loaded solid lipid nanoparticles 245
New BPO formulation 5% BPO formulation in solubilized small-size particles 246
Retinoic acid metabolism-
blocking agents
Topical rambazole 247
Oral talarozole 247
Agents controlling excess
androgen
Cyproterone acetate in lipid nanoparticles (a topical anti-androgen for use
in men and women)
248
1% cortexolone 17α-propionate cream (a topical anti-androgen
with anti-inflammatory properties that is better tolerated than tretinoin,
with rapid onset and without systemic action)
249
ASC-J9 (a curcumin analogue; reduces total inflammatory and
non-inflammatory lesions compared with placebo in moderate-to-severe
acne in men and women without adverse events)
250
SB204 (a nitric oxide-releasing donor gel, which has local antimicrobial
and anti-inflammatory actions and inhibits skin steroidogenesis resulting
in reduced androgen levels in the skin)
251
Hormone modulators such as epigallocatechin-3-gallate reduce sebum
production, inflammation and Propionibacteriumacnes viability by
suppressing IGF1 action
252
Antagonists of regulatory
neuropeptides
JNJ-10229570 (a melanocortin 1 receptor and melanocortin 5 receptor
antagonist) modulates sebaceous differentiation resulting in decreased gland
size and a reduction in lipid production
253
Afamelanotide (Nle4-D-Phe7-α-MSH; an α-melanocyte-stimulating hormone
analogue with anti-inflammatory actions)
254
5-Lipoxygenase inhibitors Zileuton (oral formulation; improves inflammatory acne and directly inhibits
sebum synthesis in a transient manner with a potency similar to that of low-dose
isotretinoin; the best alternative for oral antibiotics with minor liver toxicity)
236–238
Antimicrobial peptides Omiganan pentahydrochloride (reduces non-inflammatory and inflammatory
acne lesion counts)
255
Neutralizing antibodies
targeting and inhibiting the
activation of cytokines
Inhibitors of dipeptidyl peptidase IV and aminopeptidase N (stimulate
IL-1α receptor antagonist and reduce sebaceous hyperplasia, follicular
hyperkeratosis and inflammation)
74
Vaccines targeting microbial
products of P.acnes
Reduce P.acnes infection 256
PPAR modulator Metformin (decreases both fasting and stimulated plasma insulin levels
and reduces insulin resistance)
257
Inhibitors of
pro-inflammatory skin lipids
Free fatty acids (direct antibacterial activities against P.acnes and enhance
the innate antibacterial defence of the skin, while reducing comedone size
and overall inflammation in acne)
258–261
BPO, benzoyl peroxide; IGF1, insulin-like growth factor 1; PPAR, peroxisome proliferator-activated receptor.
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
15
© 2015 Macmillan Publishers Limited. All rights reserved
1. White,G.M. Recent findings in the epidemiologic
evidence, classification, and subtypes of acne vulgaris.
J.Am. Acad. Dermatol. 39, S34–S37 (1998).
2. Vos,T. etal. Years lived with disability (YLDs) for 1160
sequelae of 289 diseases and injuries 1990–2010:
asystematic analysis for the Global Burden of Disease
study 2010. Lancet 380, 2163–2196 (2012).
3. Gollnick,H.P. & Finlay,A. Y., Shear,N. & Global
Alliance to Improve Outcomes in Acne. Can we define
acne as a chronic disease? If so, how and when? Am.
J.Clin. Dermatol. 9, 279–284 (2008).
An important article suggesting the chronic nature
of acne.
4. Burton,J.L., Cunliffe,W.J., Stafford,I. & Shuster,S.
The prevalence of acne vulgaris in adolescence. Br.
J.Dermatol. 85, 119–126 (1971).
5. Ghodsi,S.Z., Orawa,H. & Zouboulis,C.C. Prevalence,
severity, and severity risk factors of acne in high school
pupils: a community-based study. J.Invest. Dermatol.
129, 2136–2141 (2009).
A well-planned epidemiological study on acne and a
review of the literature.
6. Thiboutot,D. etal. New insights into the management
of acne: an update from the Global Alliance to Improve
Outcomes in Acne group. J.Am. Acad. Dermatol. 60,
S1–S50 (2009).
This paper presents an update of the 2003
guideline of the Global Alliance to Improve
Outcomes in Acne group, which includes
comprehensive data about acne and its
management.
7. Dreno,B. & Poli,F. Epidemiology of acne. Dermatology
206, 7–10 (2003).
8. Centers for DiseaseControl and Prevention. NAMCS
factsheet for dermatology. CDC [online], http://
www.cdc.gov/nchs/data/ahcd/NAMCS_2010_
factsheet_dermatology.pdf (2010).
A factsheet that provides the most recent US data
about dermatology visits.
9. Centers for DiseaseControl and Prevention. Annual
number and percent distribution of ambulatory care
visits by setting type according to diagnosis group:
United States, 2009–2010. CDC [online], http://
www.cdc.gov/nchs/data/ahcd/combined_tables/
2009-2010_combined_web_table01.pdf (2010).
10. Wilmer,E.N. etal. Most common dermatologic
conditions encountered by dermatologists and
nondermatologists. Cutis 94, 285–292 (2014).
This article presents updated demographic data of
dermatology visits in the United States.
11. Yentzer,B.A. etal. Acne vulgaris in the United States:
a descriptive epidemiology. Cutis 86, 94–99 (2010).
12. McConnell,R.C., Fleischer,A.B., Williford,P.M. &
Feldman,S.R. Most topical tretinoin treatment is for
acne vulgaris through the age of 44years: an analysis
of the National Ambulatory Medical Care Survey,
1990–1994. J.Am. Acad. Dermatol. 38, 221–226
(1998).
13. Goulden,V., Clark,S.M. & Cunliffe,W.J. Post-
adolescent acne: a review of clinical features. Br.
J.Dermatol. 136, 66–70 (1997).
14. Landis,E.T., Davis,S.A., Taheri,A. & Feldman,S.R.
Top dermatologic diagnoses by age. Dermatol. Online
J. 20, 22368 (2014).
15. Goldberg,J.L. etal. Changing age of acne vulgaris
visits: another sign of earlier puberty? Pediatr.
Dermatol. 28, 645–648 (2011).
16. Davis,S.A. etal. Top dermatologic conditions in
patients of color: an analysis of nationally
representative data. J.Drugs Dermatol. 11,
466–473 (2012).
17. Perkins,A.C., Cheng,C.E., Hillebrand,G.G.,
Miyamoto,K. & Kimball,A.B. Comparison of the
epidemiology of acne vulgaris among Caucasian,
Asian, Continental Indian and African American
women. J.Eur. Acad. Dermatol. Venereol. 25,
1054–1060 (2011).
18. Bickers,D.R. etal. The burden of skin diseases: 2004
a joint project of the American Academy of
Dermatology Association and the Society for
Investigative Dermatology. J.Am. Acad. Dermatol. 55,
490–500 (2006).
19. Zouboulis,C.C. Acne as a chronic systemic disease.
Clin. Dermatol. 32, 389–396 (2014).
This article reviews the association of acne with
non-dermatological disorders, indicating that acne
could occasionally be a cutaneous phenotype of
systemic diseases.
20. Zouboulis,C.C., Jourdan,E. & Picardo,M. Acne is an
inflammatory disease and alterations of sebum
composition initiate acne lesions. J.Eur. Acad.
Dermatol. Venereol. 28, 527–532 (2014).
In this review, the authors present evidence that
acne is induced by changes in sebum lipid
composition and not only by increased seborhhoea.
21. Das,S. & Reynolds,R.V. Recent advances in acne
pathogenesis: implications for therapy. Am. J.Clin.
Dermatol. 15, 479–488 (2014).
This review article associates the recent advances in
the knowledge in acne pathogenesis with new
potential compound candidates for acne treatment.
22. Goulden,V., McGeown,C.H. & Cunliffe,W.J. The
familial risk of adult acne: a comparison between first-
degree relatives of affected and unaffected individuals.
Br. J.Dermatol. 141, 297–300 (1999).
23. Herane,M.I. & Ando,I. Acne in infancy and acne
genetics. Dermatology 206, 24–28 (2003).
24. Evans,D.M., Kirk,K.M., Nyholt,D.R., Novac,C. &
Martin,N.G. Teenage acne is influenced by genetic
factors. Br. J.Dermatol. 152, 579–581 (2005).
25. Ju,Q. etal. 2,3,7,8-Tetrachlorodibenzo-p-dioxin alters
sebaceous gland cell differentiation in vitro. Exp.
Dermatol. 20, 320–325 (2011).
26. Valeyrie-Allanore,L., Sassolas,B. & Roujeau,J.C. Drug-
induced skin, nail and hair disorders. Drug Saf. 30,
1011–1030 (2007).
27. Melnik,B.C., John,S.M. & Schmitz,G. Over-
stimulation of insulin/IGF-1 signaling by western diet
may promote diseases of civilization: lessons learnt
from laron syndrome. Nutr. Metab. (Lond.) 8, 41
(2011).
28. Mahmood,S.N. & Bowe,W.P. Diet and acne update:
carbohydrates emerge as the main culprit. J.Drugs
Dermatol. 13, 428–435 (2014).
29. Wolkenstein,P. etal. Smoking and dietary factors
associated with moderate-to-severe acne in French
adolescents and young adults: results of a survey using
a representative sample. Dermatology 230, 34–39
(2015).
30. Albuquerque,R.G., Rocha,M.A., Bagatin,E., Tufik,S.
& Andersen,M.L. Could adult female acne be
associated with modern life? Arch. Dermatol. Res. 306,
683–688 (2014).
31. Zouboulis,C.C., Schagen,S. & Alestas,T. Thesebocyte
culture: a model to study the pathophysiology of the
sebaceous gland in sebostasis, seborrhoea and acne.
Arch. Dermatol. Res. 300, 397–413 (2008).
32. Dahlhoff,M., de Angelis,M.H., Wolf,E. &
Schneider,M.R. Ligand-independent epidermal growth
factor receptor hyperactivation increases sebaceous
gland size and sebum secretion in mice. Exp. Dermatol.
22, 667–669 (2013).
33. Camera,E., Dahlhoff,M., Ludovici,M., Zouboulis,C.C.
& Schneider,M.R. Perilipin 3 modulates specific
lipogenic pathways in SZ95 sebocytes. Exp. Dermatol.
23, 759–761 (2014).
34. Dahlhoff,M. etal. PLIN2, the major perilipin regulated
during sebocyte differentiation, controls sebaceous lipid
accumulation in vitro and sebaceous gland size in vivo.
Biochim. Biophys. Acta 1830, 4642–4649 (2013).
35. Choi,C.W., Choi,J.W., Park,K.C. & Youn,S.W. Facial
sebum affects the development of acne, especially the
distribution of inflammatory acne. J.Eur. Acad.
Dermatol. Venereol. 27, 301–306 (2013).
36. Mourelatos,K., Eady,E.A., Cunliffe,W.J., Clark,S.M.
& Cove,J.H. Temporal changes in sebum excretion and
propionibacterial colonization in preadolescent children
with and without acne. Br. J.Dermatol. 156, 22–31
(2007).
37. Pappas,A. The relationship of diet and acne: a review.
Dermatoendocrinol. 1, 262–267 (2009).
38. Stewart,M.E. Sebaceous gland lipids. Semin.
Dermatol. 11, 100–105 (1992).
39. Downing,D.T., Stewart,M.E., Wertz,P.W. &
Strauss,J.S. Essential fatty acids and acne. J.Am.
Acad. Dermatol. 14, 221–225 (1986).
40. Zouboulis,C.C. Acne and sebaceous gland function.
Clin. Dermatol. 22, 360–366 (2004).
41. Ottaviani,M. etal. Peroxidated squalene induces the
production of inflammatory mediators in HaCaT
keratinocytes: a possible role in acne vulgaris. J.Invest.
Dermatol. 126, 2430–2437 (2006).
42. Smith,R.N., Braue,A., Varigos,G.A. & Mann,N.J.
The effect of a low glycemic load diet on acne vulgaris
and the fatty acid composition of skin surface
triglycerides. J.Dermatol. Sci. 50, 41–52 (2008).
43. Pappas,A., Fantasia,J. & Chen,T. Age and ethnic
variations in sebaceous lipids. Dermato-endocrinology
5, 319–324 (2013).
44. da Cunha,M.G., Fonseca,F.L. & Machado,C.D.
Androgenic hormone profile of adult women with acne.
Dermatology 226, 167–171 (2013).
45. Wei,B. etal. Higher 17α-hydroxyprogesterone levels
aggravated the severity of male adolescent acne in
northeast China. Dermatology 229, 359–362
(2014).
46. Makrantonaki,E. etal. Interplay of IGF-I and
17β-estradiol at age-specific levels in human
sebocytes and fibroblasts in vitro. Exp. Gerontol. 43,
939–946 (2008).
47. Slominski,A. etal. Steroidogenesis in the skin:
implications for local immune functions. J.Steroid
Biochem. Mol. Biol. 137, 107–123 (2013).
This article reviews the current knowledge on
cutaneous steroidogenesis and its implications in
skin diseases, including acne.
48. Krause,K., Schnitger,A., Fimmel,S., Glass,E. &
Zouboulis,C.C. Corticotropin-releasing hormone skin
signaling is receptor-mediated and is predominant in
the sebaceous glands. Horm. Metab. Res. 39,
166–170 (2007).
49. Zouboulis,C.C. etal. Corticotropin-releasing
hormone: an autocrine hormone that promotes
lipogenesis in human sebocytes. Proc. Natl Acad. Sci.
USA 99, 7148–7153 (2002).
50. Sansone,G. & Reisner,R.M. Differential rates of
conversion of testosterone to dihydrotestosterone in
acne and in normal human skin — a possible
pathogenic factor in acne. J.Invest. Dermatol. 56,
366–372 (1971).
51. Pochi,P.E. & Strauss,J.S. Sebaceous gland response
in man to the administration of testosterone,
Δ4-androstenedione, and dehydroisoandrosterone.
J.Invest. Dermatol. 52, 32–36 (1969).
52. Giltay,E.J. & Gooren,L.J. Effects of sex steroid
deprivation/administration on hair growth and skin
sebum production in transsexual males and females.
J.Clin. Endocrinol. Metab. 85, 2913–2921 (2000).
53. Rosenfield,R.L., Deplewski,D., Kentsis,A. &
Ciletti,N. Mechanisms of androgen induction of
sebocyte differentiation. Dermatology 196, 43–46
(1998).
54. Chen,W., Yang,C.C., Sheu,H.M., Seltmann,H. &
Zouboulis,C.C. Expression of peroxisome proliferator-
activated receptor and CCAAT/enhancer binding
protein transcription factors in cultured human
sebocytes. J.Invest. Dermatol. 121,
441–447 (2003).
55. Zouboulis,C.C. etal. What is the pathogenesis of
acne? Exp. Dermatol. 14, 143–152 (2005).
56. Inoue,T. etal. Expression of steroidogenic enzymes in
human sebaceous glands. J.Endocrinol. 222,
301–312 (2014).
57. Lee,S.E., Kim,J.M., Jeong,M.K., Zouboulis,C.C. &
Lee,S.H. 11β-hydroxysteroid dehydrogenase type 1 is
expressed in human sebaceous glands and regulates
glucocorticoid-induced lipid synthesis and Toll-like
receptor 2 expression in SZ95 sebocytes. Br.
J.Dermatol. 168, 47–55 (2013).
58. Aizawa,H. & Niimura,M. Elevated serum insulin-like
growth factor-1 (IGF-1) levels in women with
postadolescent acne. J.Dermatol. 22, 249–252
(1995).
59. Cappel,M., Mauger,D. & Thiboutot,D. Correlation
between serum levels of insulin-like growth factor 1,
dehydroepiandrosterone sulfate, and
dihydrotestosterone and acne lesion counts in adult
women. Arch. Dermatol. 141, 333–338 (2005).
60. Vora,S., Ovhal,A., Jerajani,H., Nair,N. &
Chakrabortty,A. Correlation of facial sebum to serum
insulin-like growth factor 1 in patients with acne. Br.
J.Dermatol. 159, 990–991 (2008).
61. Rudman,S.M., Philpott,M.P., Thomas,G.A. &
Kealey,T. The role of IGF-I in human skin and its
appendages: morphogen as well as mitogen?
J.Invest. Dermatol. 109, 770–777 (1997).
62. Deplewski,D. & Rosenfield,R.L. Growth hormone
and insulin-like growth factors have different effects on
sebaceous cell growth and differentiation.
Endocrinology 140, 4089–4094 (1999).
This article reviews the complex regulation of
sebaceous gland action through the growth
hormone and IGF1 signalling cascade.
63. Tavakkol,A., Varani,J., Elder,J.T. & Zouboulis,C.C.
Maintenance of human skin in organ culture: role for
insulin-like growth factor 1 receptor and epidermal
growth factor receptor. Arch. Dermatol. Res. 291,
643–651 (1999).
64. Smith,T.M., Cong,Z., Gilliland,K.L., Clawson,G.A.
& Thiboutot,D.M. Insulin-like growth factor-1 induces
lipid production in human SEB-1 sebocytes via sterol
response element-binding protein-1. J.Invest.
Dermatol. 126, 1226–1232 (2006).
PRIMER
16
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
65. Smith,T.M., Gilliland,K., Clawson,G.A. &
Thiboutot,D.IGF-1 induces SREBP-1 expression and
lipogenesis in SEB-1 sebocytes via activation of the
phosphoinositide 3-kinase/Akt pathway. J.Invest.
Dermatol. 128, 1286–1293 (2008).
66. Melnik,B.C. & Zouboulis,C.C. Potential role of FoxO1
and mTORC1 in the pathogenesis of Western diet-
induced acne. Exp. Dermatol. 22, 311–315 (2013).
67. Blanchard,P.G. etal. Major involvement of mTOR in
the PPARγ-induced stimulation of adipose tissue lipid
uptake and fat accretion. J.Lipid Res. 53,
1117–1125 (2012).
68. Bakan,I. & Laplante,M. Connecting mTORC1 signaling
to SREBP-1 activation. Curr. Opin. Lipidol. 23,
226–234 (2012).
69. Rosignoli,C., Nicolas,J.C., Jomard,A. & Michel,S.
Involvement of the SREBP pathway in the mode of
action of androgens in sebaceous glands in vivo. Exp.
Dermatol. 12, 480–489 (2003).
70. Ganceviciene,R., Graziene,V., Fimmel,S. &
Zouboulis,C.C. Involvement of the corticotropin-
releasing hormone system in the pathogenesis of acne
vulgaris. Br. J.Dermatol. 160, 345–352 (2009).
This paper provides evidence for the role of
neuropeptides, and especially of the most upstream
hypothalamic hormone corticotropin-releasing
hormone, in the function of the sebaceous gland and
the development of stress-induced acne.
71. Zhang,L., Li,W.H., Anthonavage,M. & Eisinger,M.
Melanocortin 5 receptor: a marker of human sebocyte
differentiation. Peptides 27, 413–420 (2006).
72. Ganceviciene,R., Böhm,M., Fimmel,S. &
Zouboulis,C.C. The role of neuropeptides in the
multifactorial pathogenesis of acne vulgaris.
Dermatoendocrinol. 1, 170–176 (2009).
73. Toyoda,M., Nakamura,M. & Morohashi,M.
Neuropeptides and sebaceous glands. Eur. J.Dermatol.
12, 422–427 (2002).
This article describes the effects of downstream
neuropeptides on sebaceous glands and their
diseases.
74. Thielitz,A. etal. Inhibitors of dipeptidyl peptidase IV
and aminopeptidase N target major pathogenetic steps
in acne initiation. J.Invest. Dermatol. 127,
1042–1051 (2007).
75. Zouboulis,C.C. Is acne vulgaris a genuine inflammatory
disease? Dermatology 203, 277–279 (2001).
76. Jeremy,A.H., Holland,D.B., Roberts,S.G.,
Thomson,K.F. & Cunliffe,W.J. Inflammatory events
are involved in acne lesion initiation. J.Invest.
Dermatol. 121, 20–27 (2003).
77. Freedberg,I., Tomic-Canic,M., Komine,M. &
Blumenberg,M. Keratins and the keratinocyte
activation cycle. J.Invest. Dermatol. 116 , 633–640
(2001).
78. Trivedi,N.R., Gilliland,K.L., Zhao,W., Liu,W. &
Thiboutot,D.M. Gene array expression profiling in
acne lesions reveals marked upregulation of genes
involved in inflammation and matrix remodeling.
J.Invest. Dermatol. 126, 1071–1079 (2006).
79. Kang,S. etal. Inflammation and extracellular matrix
degradation mediated by activated transcription factors
nuclear factor-κB and activator protein 1 in
inflammatory acne lesions in vivo. Am. J.Pathol. 166,
1691–1699 (2005).
80. Kistowska,M. etal. IL-1β drives inflammatory
responses to Propionibacterium acnes in vitro and in
vivo. J.Invest. Dermatol. 134, 677–685 (2014).
81. Choi,J.J. etal. TNF-α increases lipogenesis via JNK
and PI3K/Akt pathways in SZ95 human sebocytes.
J.Dermatol. Sci. 65, 179–188 (2012).
82. Kelhälä,H.L. etal. IL-17/Th17 pathway is activated in
acne lesions. PLoS ONE 9, e105238 (2014).
83. Alestas,T., Ganceviciene,R., Fimmel,S.,
Müller-Decker,K. & Zouboulis,C.C. Enzymes involved
in the biosynthesis of leukotriene B4 and prostaglandin
E2 are active in sebaceous glands. J.Mol. Med. (Berl.).
84, 75–87 (2006).
This paper provides robust evidence on the
involvement of inflammation and its pathways on
acne pathogenesis.
84. Zhang,Q., Seltmann,H., Zouboulis,C.C. &
Travers,J.B. Activation of platelet-activating factor
receptor in SZ95 sebocytes results in inflammatory
cytokine and prostaglandin E2 production. Exp.
Dermatol. 15, 769–774 (2006).
85. Neufang,G., Furstenberger,G., Heidt,M., Marks,F. &
Müller-Decker,K. Abnormal differentiation of epidermis
in transgenic mice constitutively expressing
cyclooxygenase-2 in skin. Proc. Natl Acad. Sci. USA 98,
7629–7634 (2001).
86. Zhang,Q., Seltmann,H., Zouboulis,C.C. &
Konger,R.L. Involvement of PPARγ in oxidative
stress-mediated prostaglandin E2 production in SZ95
human sebaceous gland cells. J.Invest. Dermatol.
126, 42–48 (2006).
87. Zouboulis,C.C., Seltmann,H. & Alestas,T. Zileuton
prevents the activation of the leukotriene pathway
and reduces sebaceous lipogenesis. Exp. Dermatol.
19, 148–150 (2010).
88. Fitz-Gibbon,S. etal. Propionibacterium acnes strain
populations in the human skin microbiome
associated with acne. J.Invest. Dermatol. 133,
2152–2160 (2013).
This article presents the P. acnes taxonomy and its
association with acne.
89. Jasson,F. etal. Different strains of
Propionibacterium acnes modulate differently the
cutaneous innate immunity. Exp. Dermatol. 22,
587–592 (2013).
90. Nagy,I. etal. Propionibacterium acnes and
lipopolysaccharide induce the expression of
antimicrobial peptides and proinflammatory
cytokines/chemokines in human sebocytes. Microbes
Infect. 8, 2195–2205 (2006).
91. Lee,D.Y. etal. Sebocytes express functional
cathelicidin antimicrobial peptides and can act to kill
Propionibacterium acnes. J.Invest. Dermatol. 128,
1863–1866 (2008).
92. Graham,G.M., Farrar,M.D., Cruse-Sawyer,J.E.,
Holland,K.T. & Ingham,E. Proinflammatory cytokine
production by human keratinocytes stimulated with
Propionibacterium acnes and P.acnes GroEL. Br.
J.Dermatol. 150, 421–428 (2004).
93. McDowell,A. etal. Propionibacterium acnes types I
and II represent phylogenetically distinct groups.
J.Clin. Microbiol. 43, 326–334 (2005).
94. Nagy,I. etal. Distinct strains of Propionibacterium
acnes induce selective human β-defensin-2 and
interleukin-8 expression in human keratinocytes
through Toll-like receptors. J.Invest. Dermatol. 124,
931–938 (2005).
95. Schaller,M. etal. Induction of a chemoattractive
proinflammatory cytokine response after stimulation
of keratinocytes with Propionibacterium acnes and
coproporphyrin III. Br. J.Dermatol. 153, 66–71
(2005).
96. Agak,G.W. etal. Propionibacterium acnes induces
an IL-17 response in acne vulgaris that is regulated
by vitamin A and vitamin D. J.Invest. Dermatol. 134,
366–373 (2014).
97. Kistowska,M. etal. Propionibacterium acnes
promotes Th17 and Th17/Th1 responses in acne
patients. J.Invest. Dermatol. 135, 110–118 (2015).
98. Li,Z.J. etal. Propionibacterium acnes activates the
NLRP3 inflammasome in human sebocytes. J.Invest.
Dermatol. 134, 2747–2756 (2014).
This paper provides the first evidence of the
inflammasome regulation by P. acnes.
99. Kim,J. Review of the innate immune response in
acne vulgaris: activation of Toll-like receptor 2 in acne
triggers inflammatory cytokine responses.
Dermatology 211, 193–198 (2005).
100. Georgel,P. etal. A Toll-like receptor 2 responsive
lipid effector pathway protects mammals against skin
infections with Gram-positive bacteria. Infect. Immun.
73, 4512–4521 (2005).
This article provides the first evidence of the role
of bacterial peptides on sebaceous lipogenesis
and inflammatory signalling.
101. Oeff,M.K. etal. Differential regulation of Toll-like
receptor and CD14 pathways by retinoids and
corticosteroids in human sebocytes. Dermatology
213, 266 (2006).
102. Selway,J.L., Kurczab,T., Kealey,T. & Langlands,K.
Toll-like receptor 2 activation and comedogenesis:
implications for the pathogenesis of acne. BMC
Dermatol. 13, 10 (2013).
103. Bakry,O.A., Samaka,R.M., Sebika,H. & Seleit,I.
Toll-like receptor 2 and P.acnes: do they trigger
initial acne vulgaris lesions? Anal. Quant. Cytopathol.
Histopathol. 36, 100–110 (2014).
104. Chronnell,C.M. etal. Human β defensin-1 and -2
expression in human pilosebaceous units:
upregulation in acne vulgaris lesions. J.Invest.
Dermatol. 117 , 1120–1125 (2001).
105. Harrison,W.J., Bull,J.J., Seltmann,H.,
Zouboulis,C.C. & Philpott,M.P. Expression of
lipogenic factors galectin-12, resistin, SREBP-1, and
SCD in human sebaceous glands and cultured
sebocytes. J.Invest. Dermatol. 127, 1309–1317
(2007).
106. Nakatsuji,T. etal. Antimicrobial property of lauric acid
against Propionibacterium acnes: its therapeutic
potential for inflammatory acne vulgaris. J.Invest.
Dermatol. 129, 2480–2488 (2009).
107. Nakatsuji,T. etal. Sebum free fatty acids enhance the
innate immune defense of human sebocytes by
upregulating β-defensin-2 expression. J.Invest.
Dermatol. 130, 985–994 (2010).
108. Bissonnette,R. etal. Changes in serum free
testosterone, sleep patterns, and 5-alpha-reductase
type I activity influence changes in sebum excretion in
female subjects. Skin Res. Technol. 21 , 47–53 (2015).
109. Rasmussen,J.E. Diet and acne. Int. J.Dermatol. 16,
488–492 (1977).
110 . Melnik,B.C. & Schmitz,G. Role of insulin, insulin-like
growth factor-1, hyperglycaemic food and milk
consumption in the pathogenesis of acne vulgaris. Exp.
Dermatol. 18, 833–841 (2009).
111. Downing,D.T., Strauss,J.S. & Pochi,P.E. Changes in
skin surface lipid composition induced by severe caloric
restriction in man. Am. J.Clin. Nutr. 25,
365–367 (1972).
112 . Pochi,P.E., Downing,D.T. & Strauss,J.S. Sebaceous
gland response in man to prolonged total caloric
deprivation. J.Invest. Dermatol. 55, 303–309 (1970).
113 . MacDonald,I. Changes in the fatty acid composition of
sebum associated with high carbohydrate diets. Nature
203, 1067–1068 (1964).
114 . Cordain,L. etal. Acne vulgaris: a disease of Western
civilization. Arch. Dermatol. 138, 1584–1590 (2002).
This paper presents clinicoepidemiological evidence
of nutrition induction of acne.
115 . Arora,M.K., Seth,S., Dayal,S., Trehan,A.S. &
Seth,M. Serum lipid profile in female patients with
severe acne vulgaris. Clin. Lab. 60, 1201–1205
(2014).
116 . Lu,P.H. & Hsu,C.H. Body mass index is negatively
associated with acne lesion counts in Taiwanese women
with post-adolescent acne. J.Eur. Acad. Dermatol.
Venereol. http://dx.doi.org/10.1111/jdv.12754 (2014).
117 . Di Landro,A. etal. Family history, body mass index,
selected dietary factors, menstrual history, and risk of
moderate to severe acne in adolescents and young
adults. J.Am. Acad. Dermatol. 67, 1129–1135
(2012).
118 . Schäfer,T., Nienhaus,A., Vieluf,D., Berger,J. &
Ring,J. Epidemiology of acne in the general
population: the risk of smoking. Br. J.Dermatol. 145,
100–104 (2001).
119 . Rombouts,S., Nijsten,T. & Lambert,J. Cigarette
smoking and acne in adolescents: results from a cross-
sectional study. J.Eur. Acad. Dermatol. Venereol. 21,
326–333 (2007).
120. Yang,Y.S. etal. Cigarette smoke-induced interleukin-1
alpha may be involved in the pathogenesis of adult
acne. Ann. Dermatol. 26, 11–16 (2014).
This article explains how cigarette smoke-induced
IL-1α production may be involved in the
pathogenesis of adult acne.
121. Melnik,B., Jansen,T. & Grabbe,S. Abuse of anabolic-
androgenic steroids and bodybuilding acne:
anunderestimated health problem. J.Dtsch.
Dermatol. Ges. 5, 110–117 (2007).
122. Szabó,K. & Kemény,L. Studying the genetic
predisposing factors in the pathogenesis of acne
vulgaris. Hum. Immunol. 72, 766–773 (2011).
123. Tasli,L. etal. Insulin-like growth factor-I gene
polymorphism in acne vulgaris. J.Eur. Acad. Dermatol.
Venereol. 27, 254–257 (2013).
124. Amr,K., Abdel-Hameed,M., Sayed,K., Nour-Edin,F. &
Abdel Hay,R. The Pro12Ala polymorphism of the gene
for peroxisome proliferator activated receptor-gamma
is associated with a lower Global Acne Grading System
score in patients with acne vulgaris. Clin. Exp.
Dermatol. 39, 741–745 (2014).
125. Younis,S. & Javed,Q. The interleukin-6 and
interleukin-1A gene promoter polymorphism is
associated with the pathogenesis of acne vulgaris.
Arch. Dermatol. Res. 307, 365–370 (2015).
126. He,L. etal. Two new susceptibility loci 1q24.2 and
11p11.2 confer risk to severe acne. Nat. Commun. 5,
2870 (2014).
127. Navarini,A.A. etal. Genome-wide association study
identifies three novel susceptibility loci for severe acne
vulgaris. Nat. Commun. 5, 4020 (2014).
This is a large genome-wide association study in
patients with acne compared with healthy controls.
128. Zhang,M., Qureshi,A.A., Hunter,D.J. & Han,J.
Agenome-wide association study of severe teenage
acne in European Americans. Hum. Genet. 133,
259–264 (2014).
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
17
© 2015 Macmillan Publishers Limited. All rights reserved
129. Bek-Thomsen,M., Lomholt,H.B., Scavenius,C.,
Enghild,J.J. & Brüggemann,H. Proteome analysis of
human sebaceous follicle infundibula extracted from
healthy and acne-affected skin. PLoS ONE 9, e107908
(2014).
130. Katsambas,A.D., Cunliffe,W.J. & Zouboulis,C.C.
inPathogenesis and Treatment of Acne and Rosacea
(eds Zouboulis,C.C. etal.) 213–221 (Springer, 2014).
131. Lucky,A.W., Dessinioti,C. & Katsambas,A.D. in
Pathogenesis and Treatment of Acne and Rosacea (eds
Zouboulis,C.C. etal.) 243–249 (Springer, 2014).
132. Antoniou,C., Dessinioti,C., Stratigos,A.J. &
Katsambas,A.D. Clinical and therapeutic approach to
childhood acne: an update. Pediatr. Dermatol. 26,
373–380 (2009).
133. Eichenfield,L.F. etal. Evidence-based
recommendations for the diagnosis and treatment of
pediatric acne. Pediatrics 131, S163–S186 (2013).
134. Chiang,A., Hafeez,F. & Maibach,H.I. Skin lesion
metrics: role of photography in acne. J.Dermatolog.
Treat. 25, 100–105 (2014).
135. Burke,B.M. & Cunliffe,W.J. The assessment of acne
vulgaris — the Leeds technique. Br. J.Dermatol. 111,
83–92 (1984).
136. Ramli,R., Malik,A.S., Hani,A.F. & Jamil,A. Acne
analysis, grading and computational assessment
methods: an overview. Skin Res. Technol. 18, 1–14
(2012).
A review of the existing computational evaluation
methods and current developments.
137. Lucky,A.W. etal. A multirater validation study to
assess the reliability of acne lesion counting. J.Am.
Acad. Dermatol. 35, 559–565 (1996).
138. Plewig,G. Acne: Morphogenesis and Treatment
(Springer-Verlag Berlin Heidelberg, 1975).
139. O’brien,S., Lewis,J. & Cunliffe,W. The Leeds revised
acne grading system. J.Dermatol. Treat. 9, 215–220
(1998).
This article presents the most sophisticated
method for assessing classic acne severity and
efficacy of acne treatment studies though a global
grading of acne lesions.
140. Tan,J.K. etal. Evaluation of essential clinical
components and features of current acne global
grading scales. J.Am. Acad. Dermatol. 69, 754–761
(2013).
141. Tan,J. etal. Acne severity grading: determining
essential clinical components and features using a
Delphi consensus. J.Am. Acad. Dermatol. 67,
187–193 (2012).
142. Cook,C.H., Centner,R.L. & Michaels,S.E. An acne
grading method using photographic standards. Arch.
Dermatol. 115 , 571–575 (1979).
143. Rizova,E. & Kligman,A. New photographic techniques
for clinical evaluation of acne. J.Eur. Acad. Dermatol.
Venereol. 15, S13–S18 (2001).
144. Patwardhan,S.V., Kaczvinsky,J.R., Joa,J.F. &
Canfield,D. Auto-classification of acne lesions using
multimodal imaging. J.Drugs Dermatol. 12,
746–756 (2013).
145. Stamatas,G.N. & Kollias,N. in Pathogenesis and
Treatment of Acne and Rosacea (eds Zouboulis,C.C.
etal.) 331–340 (Springer, 2014).
This book chapter presents current and future
technologies for imaging and assessment of acne
lesions.
146. Dessinioti,C., Antoniou,C. & Katsambas,A. Acneiform
eruptions. Clin. Dermatol. 32, 24–34 (2014).
147. Katsambas,A.D., Dessinioti,C. & Cunliffe,W.J. in
Pathogenesis and Treatment of Acne and Rosacea (eds
Zouboulis,C.C. etal.) 223–226 (Springer, 2014).
148. Chen,W. etal. Acne-associated syndromes: models for
better understanding of acne pathogenesis. J.Eur.
Acad. Dermatol. Venereol. 25, 637–646 (2011).
149. Melnik,B.C., John,S.M. & Plewig,G. Acne: risk
indicator for increased body mass index and insulin
resistance. Acta Derm. Venereol. 93, 644–649
(2013).
150. Adebamowo,C.A. etal. Milk consumption and acne in
teenaged boys. J.Am. Acad. Dermatol. 58, 787–793
(2008).
151. Aksu,A.E. etal. Acne: prevalence and relationship
with dietary habits in Eskisehir, Turkey. J.Eur. Acad.
Dermatol. Venereol. 26, 1503–1509 (2012).
152. Kaymak,Y. etal. Dietary glycemic index and glucose,
insulin, insulin-like growth factor I, insulin-like growth
factor binding protein 3, and leptin levels in patients
with acne. J.Am. Acad. Dermatol. 57, 819–823
(2007).
153. Smith,R.N., Mann,N.J., Braue,A., Mäkeläinen,H.
&Varigos,G.A. The effect of a high-protein, low
glycemic-load diet versus a conventional, high glycemic-
load diet on biochemical parameters associated with
acne vulgaris: a randomized, investigator-masked,
controlled trial. J.Am. Acad. Dermatol. 57, 247–256
(2007).
This is one of the first well-planned clinical studies
to evaluate the effectiveness of fatty acids on acne
development and severity.
154. Kwon,H.H. etal. Clinical and histological effect of a
low glycaemic load diet in treatment of acne vulgaris in
Korean patients: a randomized, controlled trial. Acta
Derm. Venereol. 92, 241–246 (2012).
155. Jung,J.Y. etal. Effect of dietary supplementation with
omega-3 fatty acid and gamma-linolenic acid on acne
vulgaris: a randomised, double-blind, controlled trial.
Acta Derm. Venereol. 94, 521–525 (2014).
156. Capitanio,B. etal. Underestimated clinical features of
postadolescent acne. J.Am. Acad. Dermatol. 63,
782–788 (2010).
157. Gollnick,H. etal. Management of acne: a report from a
Global Alliance to Improve Outcomes in Acne. J.Am.
Acad. Dermatol. 49, S1–S37 (2003).
158. Strauss,J.S. etal. Guidelines of care for acne vulgaris
management. J.Am. Acad. Dermatol. 56, 651–663
(2007).
159. Nast,A. etal. European evidence-based (S3) guidelines
for the treatment of acne. J.Eur. Acad. Dermatol.
Venereol. 26, S1–S29 (2012).
This paper presents guidelines for acne treatment
and a current review on acne aetiopathogenesis.
160. Dréno,B. etal. European recommendations on the use
of oral antibiotics for acne. Eur. J.Dermatol. 14,
391–399 (2004).
161. Layton,A.M., Dreno,B., Gollnick,H.P. &
Zouboulis,C.C. A review of the European Directive for
prescribing systemic isotretinoin for acne vulgaris.
J.Eur. Acad. Dermatol. Venereol. 20, 773–776
(2006).
162. Williams,H.C., Dellavalle,R.P. & Garner,S. Acne
vulgaris. Lancet 379, 361–372 (2012).
163. Del Rosso,J.Q. & Leyden,J.J. Status report on
antibiotic resistance: implications for the
dermatologist. Dermatol. Clin. 25, 127–132 (2007).
164. Chien,A.L., Voorhees,J.J. & Kang,S. Fitzpatrick’s
Dermatology in Medicine (McGraw-Hill, 2008).
165. Benkoussa,M., Brand,C., Delmotte,M.H.,
Formstecher,P. & Lefebvre,P. Retinoic acid receptors
inhibit AP1 activation by regulating extracellular signal-
regulated kinase and CBP recruitment to an AP1-
responsive promoter. Mol. Cell. Biol. 22, 4522–4534
(2002).
166. Liu,P.T., Krutzik,S.R., Kim,J. & Modlin,R.L. Cutting
edge: all-trans retinoic acid down-regulates TLR2
expression and function. J.Immunol. 174,
2467–2470 (2005).
167. Culp,L., Moradi Tuchayi,S., Alinia,H. & Feldman,S.R.
Tolerability of topical retinoids: are there clinically
meaningful differences among topical retinoids?
J.Cutan. Med. Surg. http://dx.doi.
org/10.1177/1203475415591117 (2015).
168. Tanghetti,E.A. & Popp,K.F. A current review of topical
benzoyl peroxide: new perspectives on formulation and
utilization. Dermatol. Clin. 27, 17–24 (2009).
169. Fakhouri,T., Yentzer,B.A. & Feldman,S.R.
Advancement in benzoyl peroxide-based acne
treatment: methods to increase both efficacy and
tolerability. J.Drugs Dermatol. 8, 657–661 (2009).
170. Jacobs,A., Starke,G., Rosumeck,S. & Nast,A.
Systematic review on the rapidity of the onset of action
of topical treatments in the therapy of mild-to-
moderate acne vulgaris. Br. J.Dermatol. 170,
557–564 (2014).
A systematic review of new results in the
comparative speed of acne improvement with
different agents.
171. Zouboulis,C.C., Fischer,T.C., Wohlrab,J., Barnard,J.
& Alió,A.B. Study of the efficacy, tolerability, and
safety of 2 fixed-dose combination gels in the
management of acne vulgaris. Cutis 84, 223–229
(2009).
172. Zouboulis,C.C. etal. A multicentre, single-blind,
randomized comparison of a fixed clindamycin
phosphate/tretinoin gel formulation (Velac) applied
once daily and a clindamycin lotion formulation
(Dalacin T) applied twice daily in the topical treatment
of acne vulgaris. Br. J.Dermatol. 143, 498–505
(2000).
173. Abdel-Naser,M.B. & Zouboulis,C.C. Clindamycin
phosphate/tretinoin gel formulation in the treatment of
acne vulgaris. Expert Opin. Pharmacother. 9,
2931–2937 (2008).
174. Aslam,I., Fleischer,A. & Feldman,S. Emerging drugs
for the treatment of acne. Expert Opin. Emerg. Drugs
20, 91–101 (2015).
This paper reviews new anti-acne drugs.
175. Dréno,B. etal. Adult female acne: a new paradigm.
J.Eur. Acad. Dermatol. Venereol. 27, 1063–1070
(2013).
176. Gollnick,H.P., Graupe,K. & Zaumseil,R.P. Azelaic
acid 15% gel in the treatment of acne vulgaris.
Combined results of two double-blind clinical
comparative studies. J.Dtsch. Dermatol. Ges. 2,
841–847 (2004).
177. Thielitz,A. etal. A randomized investigator-blind
parallel-group study to assess efficacy and safety of
azelaic acid 15% gel versus adapalene 0.1% gel in the
treatment and maintenance treatment of female adult
acne. J.Eur. Acad. Dermatol. Venereol. 29, 789–796
(2015).
178. Garner,S.E. etal. Minocycline for acne vulgaris:
efficacy and safety. Cochrane Database Syst. Rev. 8,
CD002086 (2012).
179. Fleischer,A.B., Dinehart,S., Stough,D. & Plott,R.T.
Safety and efficacy of a new extended-release
formulation of minocycline. Cutis 78, 21–31 (2006).
180. Dreno,B. etal. Antibiotic stewardship in dermatology:
limiting antibiotic use in acne. Eur. J.Dermatol. 24,
330–334 (2014).
181. Lee,Y.H., Liu,G., Thiboutot,D.M., Leslie,D.L. &
Kirby,J.S. A retrospective analysis of the duration of
oral antibiotic therapy for the treatment of acne
among adolescents: investigating practice gaps and
potential cost-savings. J.Am. Acad. Dermatol. 71,
70–76 (2014).
182. Thevarajah,S., Balkrishnan,R., Camacho,F.T.,
Feldman,S.R. & Fleischer,A.B. Trends in prescription
of acne medication in the US: shift from antibiotic to
non-antibiotic treatment. J.Dermatolog. Treat. 16,
224–228 (2005).
183. Davis,S.A., Sandoval,L.F., Gustafson,C.J.,
Feldman,S.R. & Cordoro,K.M. Treatment of
preadolescent acne in the United States: an analysis of
nationally representative data. Pediatr. Dermatol. 30,
689–694 (2013).
184. Arrington,E.A., Patel,N.S., Gerancher,K. &
Feldman,S.R. Combined oral contraceptives for the
treatment of acne: a practical guide. Cutis 90, 83–90
(2012).
This is a concise paper on the available combined
oral contraceptives for acne treatment from the
points of view of both the dermatologists and the
gynaecologists.
185. Landis,E.T. etal. Isotretinoin and oral contraceptive
use in female acne patients varies by physician
specialty: analysis of data from the National
Ambulatory Medical Care Survey. J.Dermatolog.
Treat. 23, 272–277 (2012).
186. Zouboulis,C.C. & Bettoli,V. Management of severe
acne. Br. J.Dermatol. 172, S27–S36 (2015).
187. Brown,J., Farquhar,C., Lee,O., Toomath,R. &
Jepson,R.G. Spironolactone versus placebo or in
combination with steroids for hirsutism and/or acne.
Cochrane Database Syst. Rev. 2, CD000194 (2009).
188. Sandoval,L.F., Hartel,J.K. & Feldman,S.R. Current
and future evidence-based acne treatment: a review.
Expert Opin. Pharmacother. 15, 173–192 (2014).
189. Leyden,J.J., McGinley,K.J. & Foglia,A.N. Qualitative
and quantitative changes in cutaneous bacteria
associated with systemic isotretinoin therapy for acne
conglobata. J.Invest. Dermatol. 86, 390–393 (1986).
190. Wessels,F., Anderson,A.N. & Kropman,K. The cost-
effectiveness of isotretinoin in the treatment of acne.
Part 1. A meta-analysis of effectiveness literature.
S.Afr. Med. J. 89, 780–784 (1999).
191. Zouboulis,C.C. The truth behind this undeniable
efficacy — recurrence rates and relapse risk factors of
acne treatment with oral isotretinoin. Dermatology
212, 99–100 (2006).
192. Leyden,J.J., Del Rosso,J.Q. & Baum,E.W. The use
of isotretinoin in the treatment of acne vulgaris: clinical
considerations and future directions. J.Clin. Aesthet.
Dermatol. 7, S3–S21 (2014).
193. Rohrback,J.M., Fleischer,A.B., Krowchuk,D.P. &
Feldman,S.R. Depression is not common in
isotretinoin-treated acne patients. J.Dermatolog.
Treat. 15, 252 (2004).
194. Jordan,A.Y. etal. Does the teratogenicity of
isotretinoin outweigh its benefits? J.Dermatolog.
Treat. 16, 190–192 (2005).
195. Webster,G.F., Leyden,J.J. & Gross,J.A. Comparative
pharmacokinetic profiles of a novel isotretinoin
formulation (isotretinoin-Lidose) and the innovator
PRIMER
18
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
isotretinoin formulation: a randomized, 4-treatment,
crossover study. J.Am. Acad. Dermatol. 69, 762–
767 (2013).
196. Barnes,L.E., Al-Dabagh,A., Huang,W.W. &
Feldman,S.R. Common reasons why acne patients
call the office. Dermatol. Online J. 20, 22609 (2014).
197. Fleischer,A.B., Simpson,J.K., McMichael,A. &
Feldman,S.R. Are there racial and sex differences in
the use of oral isotretinoin for acne management in
the United States? J.Am. Acad. Dermatol. 49,
662–666 (2003).
198. Kosaka,S., Kawana,S., Zouboulis,C.C., Hasan,T. &
Ortel,B. Targeting of sebocytes by aminolevulinic
acid-dependent photosensitization. Photochem.
Photobiol. 82, 453–457 (2006).
199. Morton,C.A., Szeimies,R.M., Sidoroff,A. &
Braathen,L.R. European guidelines for topical
photodynamic therapy part 2: emerging indications
— field cancerization, photorejuvenation and
inflammatory/infective dermatoses. J.Eur. Acad.
Dermatol. Venereol. 27, 672–679 (2013).
200. Zheng,W. etal. Evidence-based review of
photodynamic therapy in the treatment of acne. Eur.
J.Dermatol. 24, 444–456 (2014).
A helpful recent review on photodynamic therapy
for the treatment of acne.
201. Taylor,M.N. & Gonzalez,M.L. The practicalities of
photodynamic therapy in acne vulgaris. Br.
J.Dermatol. 160, 1140–1148 (2009).
202. Hamilton,F.L. etal. Laser and other light therapies
for the treatment of acne vulgaris: systematic review.
Br. J.Dermatol. 160, 1273–1285 (2009).
203. Yentzer,B.A. etal. An exploratory study of adherence
to topical benzoyl peroxide in patients with acne
vulgaris. J.Am. Acad. Dermatol. 60, 879–880
(2009).
204. Balkrishnan,R., Kulkarni,A.S., Cayce,K. &
Feldman,S.R. Predictors of healthcare outcomes and
costs related to medication use in patients with acne
in the United States. Cutis 77, 251–255 (2006).
205. Lott,R., Taylor,S.L., O’Neill,J.L., Krowchuk,D.P. &
Feldman,S.R. Medication adherence among acne
patients: a review. J.Cosmet. Dermatol. 9, 160–166
(2010).
206. Yentzer,B.A. etal. A randomized controlled pilot
study of strategies to increase adherence in teenagers
with acne vulgaris. J.Am. Acad. Dermatol. 64,
793–795 (2011).
This study shows the importance of frequent visits
during treatment in adherence improvement.
207. Feldman,S.R. & Chen,D.M. How patients
experience and manage dryness and irritation from
acne treatment. J.Drugs Dermatol. 10, 605–608
(2011).
208. Feneran,A.N., Kaufman,W.S., Dabade,T.S. &
Feldman,S.R. Retinoid plus antimicrobial
combination treatments for acne. Clin. Cosmet.
Investig. Dermatol. 4, 79–92 (2011).
209. Yentzer,B.A. etal. Simplifying regimens promotes
greater adherence and outcomes with topical acne
medications: a randomized controlled trial. Cutis 86,
103–108 (2010).
210. Tan,X. etal. Medication adherence, healthcare costs
and utilization associated with acne drugs in Medicaid
enrollees with acne vulgaris. Am. J.Clin. Dermatol.
14, 243–251 (2013).
This large-scale study offers useful data about
adherence to acne medication.
211 . Halvorsen,J.A. etal. Suicidal ideation, mental health
problems, and social impairment are increased in
adolescents with acne: a population-based study.
J.Invest. Dermatol. 131, 363–370 (2011).
This study offers helpful information about the
psychological impact of acne.
212. Uhlenhake,E., Yentzer,B.A. & Feldman,S.R. Acne
vulgaris and depression: a retrospective examination.
J.Cosmet. Dermatol. 9, 59–63 (2010).
213. Layton,A.M., Henderson,C.A. & Cunliffe,W.J.
Aclinical evaluation of acne scarring and its incidence.
Clin. Exp. Dermatol. 19, 303–308 (1994).
214. Zouboulis,C.C., Zouridaki,E., Rosenberger,A. &
Dalkowski,A. Current developments and uses of
cryosurgery in the treatment of keloids and
hypertrophic scars. Wound Repair Regen. 10,
98–102 (2002).
215. Jacob,C.I., Dover,J.S. & Kaminer,M.S. Acne
scarring: a classification system and review of
treatment options. J.Am. Acad. Dermatol. 45,
109–117 (2001).
216. Rivera,A.E. Acne scarring: a review and current
treatment modalities. J.Am. Acad. Dermatol. 59,
659–676 (2008).
A comprehensive review of the current treatment
options for acne scars.
217. Motley,R.J. & Finlay,A.Y. How much disability is
caused by acne? Clin. Exp. Dermatol. 14, 194–198
(1989).
218. Cunliffe,W.J. Acne and unemployment. Br.
J.Dermatol. 115 , 386 (1986).
219. Tasoula,E. etal. The impact of acne vulgaris on quality
of life and psychic health in young adolescents in
Greece. Results of a population survey. An. Bras.
Dermatol. 87, 862–869 (2012).
220. Hayashi,N. etal. A cross-sectional analysis of quality
of life in Japanese acne patients using the Japanese
version of Skindex-16. J.Dermatol. 31, 971–976
(2004).
221. Tedeschi,A., Dall’Oglio,F., Micali,G., Schwartz,R.A.
& Janniger,C.K. Corrective camouflage in pediatric
dermatology. Cutis 79, 110–112 (2007).
222. Loney,T., Standage,M. & Lewis,S. Not just ‘skin deep’:
psychosocial effects of dermatological-related social
anxiety in a sample of acne patients. J.Health Psychol.
13, 47–54 (2008).
223. Mallon,E. etal. The quality of life in acne:
acomparison with general medical conditions using
generic questionnaires. Br. J.Dermatol. 140,
672–676 (1999).
224. Ohayon,M.M. Epidemiology of depression and its
treatment in the general population. J.Psychiatr. Res.
41, 207–213 (2007).
225. Kellett,S.C. & Gawkrodger,D.J. The psychological
and emotional impact of acne and the effect of
treatment with isotretinoin. Br. J.Dermatol. 140,
273–282 (1999).
226. Gupta,M.A. & Gupta,A.K. Depression and suicidal
ideation in dermatology patients with acne, alopecia
areata, atopic dermatitis and psoriasis. Br.
J.Dermatol. 139, 846–850 (1998).
227. Goodman,G.J. Post-acne scarring: a short review of
its pathophysiology. Australas. J.Dermatol. 42,
84–90 (2001).
228. Zouboulis,C.C. & Böhm,M. Neuroendocrine
regulation of sebocytes — a pathogenetic link between
stress and acne. Exp. Dermatol. 13,
S31–S35 (2004).
229. Schulpis,K., Georgala,S., Papakonstantinou,E.D. &
Michas,T. Psychological and sympatho-adrenal status
in patients with cystic acne. J.Eur. Acad. Dermatol.
Venereol. 13, 24–27 (1999).
230. Jones-Caballero,M., Chren,M.M., Soler,B.,
Pedrosa,E. & Peñas,P.F. Quality of life in mild to
moderate acne: relationship to clinical severity and
factors influencing change with treatment. J.Eur. Acad.
Dermatol. Venereol. 21, 219–226 (2007).
231. Newton,J.N., Mallon,E., Klassen,A., Ryan,T.J. &
Finlay,A.Y. The effectiveness of acne treatment:
anassessment by patients of the outcome of therapy.
Br. J.Dermatol. 137, 563–567 (1997).
232. Murray,C.J. etal. GBD 2010: design, definitions, and
metrics. Lancet 380, 2063–2066 (2012).
233. Hay,R.J. etal. The global burden of skin disease in
2010: an analysis of the prevalence and impact of skin
conditions. J.Invest. Dermatol. 134,
1527–1534 (2014).
234. Karimkhani,C. etal. Global burden of skin disease as
reflected in Cochrane Database of Systematic Reviews.
JAMA Dermatol. 150, 945–951 (2014).
This article shows the imbalance of research
devoted to different skin diseases and its burden.
235. Karimkhani,C. etal. Comparing cutaneous research
funded by the National Institute of Arthritis and
Musculoskeletal and Skin Diseases with 2010 Global
Burden of Disease results. PLoS ONE 9, e102122
(2014).
236. Zouboulis,C.C. Zileuton, a new efficient and safe
systemic anti-acne drug. Dermatoendocrinol. 1,
188–192 (2009).
The article presents the effectiveness of a systemic
anti-inflammatory leukotriene 5 inhibitor on acne.
237. Zouboulis,C.C. etal. A new concept for acne therapy:
a pilot study with zileuton, an oral 5-lipoxygenase
inhibitor. Arch. Dermatol. 139, 668–670 (2003).
238. Zouboulis,C.C., Saborowski,A. & Boschnakow,A.
Zileuton, an oral 5-lipoxygenase inhibitor, directly
reduces sebum production. Dermatology 210, 36–38
(2005).
239. Sakamoto,F.H. etal. Selective photothermolysis to
target sebaceous glands: theoretical estimation of
parameters and preliminary results using a free
electron laser. Lasers Surg. Med. 44, 175–183
(2012).
240. Dréno,B. etal. Development and evaluation of a
Global Acne Severity Scale (GEA Scale) suitable for
France and Europe. J.Eur. Acad. Dermatol. Venereol.
25, 43–48 (2011).
241. Department of Health and HumanServices. Acne
vulgaris: developing drugs for treatment. FDA [online],
http://www.fda.gov/downloads/Drugs/./Guidances/
UCM071292.pdf (2005).
242. Degitz, K., Placzek, M., Borelli, C. & Plewig, G.
Pathophysiology of acne. J.Dtsch. Dermatol. Ges. 5,
316–323 (2007).
243. Zouboulis, C.C. etal. What is the pathogenesis of
acne? Exp. Dermatol. 14, 143–153 (2005).
244. Fresno Contreras,M.J., Jiménez Soriano,M.M. &
Ramírez Diéguez,A. In vitro percutaneous absorption
of all-trans retinoic acid applied in free form or
encapsulated in stratum corneum lipid liposomes. Int.
J.Pharm. 297, 134–145 (2005).
245. Jain,A.K. etal. Adapalene loaded solid lipid
nanoparticles gel: an effective approach for acne
treatment. Colloids Surf. BBiointerfaces 121,
222–229 (2014).
246. Leyden,J. New developments in topical antimicrobial
therapy for acne. J.Drugs Dermatol. 7, S8–S11
(2008).
247. Geria,A.N. & Scheinfeld,N.S. Talarozole, a selective
inhibitor of P450 mediated all-trans retinoic acid for
the treatment of psoriasis and acne. Curr. Opin.
Investig. Drugs 9, 1228–1237 (2008).
248. Stecová,J. etal. Cyproterone acetate loading to lipid
nanoparticles for topical acne treatment: particle
characterisation and skin uptake. Pharm. Res. 24,
991–1000 (2007).
249. Trifu,V. etal. Cortexolone 17α-propionate 1% cream,
a new potent antiandrogen for topical treatment of
acne vulgaris. A pilot randomized, double-blind
comparative study versus placebo and tretinoin
0•05% cream. Br. J.Dermatol. 165, 177–183
(2011).
250. Soh,S.F. etal. Determination of androgen receptor
degradation enhancer ASC J9® in mouse sera and
organs with liquid chromatography tandem mass
spectrometry. J.Pharm. Biomed. Anal. 88, 117–122
(2014).
251. Rico, J., Quiring, J., Hollenbach, S., Enloe, C. & Stasko,
N. Phase 2 study of efficacy and safety of SB204 in the
treatment of acne vulgaris. J.Invest. Dermatol. 134,
LB838 (2014).
252. Yoon,J.Y., Kwon,H.H., Min,S.U., Thiboutot,D.M. &
Suh,D.H. Epigallocatechin-3 gallate improves acne in
humans by modulating intracellular molecular targets
and inhibiting P.acnes. J.Invest. Dermatol. 133,
429–440 (2013).
253. Eisinger,M. etal. A melanocortin receptor 1 and 5
antagonist inhibits sebaceous gland differentiation and
the production of sebum-specific lipids. J.Dermatol.
Sci. 63, 23–32 (2011).
254. Böhm,M., Ehrchen,J. & Luger,T.A. Beneficial effects
of the melanocortin analogue Nle4-D-Phe7-α MSH in
acne vulgaris. J.Eur. Acad. Dermatol. Venereol. 28,
108–111 (2014).
255. Melo,M.N., Dugourd,D. & Castanho,M.A.
Omiganan pentahydrochloride in the front line of
clinical applications of antimicrobial peptides.
RecentPat. Antiinfect. Drug Discov. 1, 201–207
(2006).
256. Nakatsuji,T. etal. Vaccination targeting a surface
sialidase of P.acnes: implication for new treatment of
acne vulgaris. PLoS ONE 3, e1551 (2008).
257. Mitkov,M., Pehlivanov,B. & Terzieva,D. Metformin
versus rosiglitazone in the treatment of polycystic
ovary syndrome. Eur. J.Obstet. Gynecol. Reprod. Biol.
126, 93–98 (2006).
258. Huang,W.C. etal. Anti-bacterial and anti-
inflammatory properties of capric acid against
Propionibacterium acnes: a comparative study with
lauric acid. J.Dermatol. Sci. 73, 232–240 (2014).
259. Morganti,P. etal. Topical clindamycin 1% versus
linoleic acid-rich phosphatidylcholine and nicotinamide
4% in the treatment of acne: a multicentre-randomized
trial. Int. J.Cosmet. Sci. 33, 467–476 (2011).
260. Letawe,C., Boone,M. & Piérard,G.E. Digital image
analysis of the effect of topically applied linoleic acid
on acne microcomedones. Clin. Exp. Dermatol. 23,
56–58 (1998).
261. Pavicic,T., Wollenweber,U., Farwick,M. &
Korting,H.C. Anti-microbial and -inflammatory activity
and efficacy of phytosphingosine: an in vitro and in vivo
study addressing acne vulgaris. Int. J.Cosmet. Sci. 29,
181–190 (2007).
PRIMER
NATURE REVIEWS
|
DISEASE PRIMERS VOLUME 1
|
2015
|
19
© 2015 Macmillan Publishers Limited. All rights reserved
Author contributions
Introduction (S.M.T., C.C.Z. and S.R.F.); Epidemiology (S.M.T.,
C.C.Z. and S.R.F.); Mechanisms/pathophysiology (S.M.T, E.M.,
R.G., C.D., C.C.Z. and S.R.F.); Diagnosis, screening and
prevention (S.M.T., E.M., R.G., C.D., C.C.Z. and S.R.F.);
Management (S.M.T., C.C.Z. and S.R.F.); Quality of life
(S.M.T., E.M., R.G., C.D., C.C.Z. and S.R.F.); Outlook (S.M.T.,
C.C.Z. and S.R.F.); overview of Primer (S.R.F.). S.M.T. and
E.M. contributed equally as first authors. S.R.F. and C.C.Z.
contributed equally as senior authors.
Competing interests
S.M.T. has no conflicts to disclose. E.M. has received an
honorarium and a grant from Immundiagnostik. R.G. is a
consultant for L’Oreal, and received honoraria as a speaker for
Bioderma, Stiefel/GlaxoSmithKline and LEO Pharma. C.D. has
received an honorarium as a speaker for Stiefel/
GlaxoSmithKline. S.R.F. is a speaker for Janssen and Taro; he is
also a consultant and speaker for Galderma, Stiefel/
GlaxoSmithKline, Abbott Laboratories and LEO Pharma. S.R.F.
has received grants from Galderma, Janssen, Abbott
Laboratories, Amgen, Stiefel/GlaxoSmithKline, Celgene and
Anacor. S.R.F. is also a consultant for Amgen, Baxter, Caremark,
Gerson Lehrman Group, Guidepoint Global, HanAll
Pharmaceutical, Kikaku, Eli Lilly, Merck, Merz, Mylan, Novartis,
Pfizer, Qurient, Suncare Research and Xenoport. S.R.F. is on an
advisory board for Pfizer. S.R.F. is also the founder of and holds
stock in Causa Research, and holds stock and is the majority
owner in Medical Quality Enhancement Corporation, and he
receives royalties from UpToDate and Xlibris. The Center for
Dermatology Research, Wake Forest School of Medicine, North
Carolina, USA, is supported by an unrestricted educational
grant from Galderma Laboratories. C.C.Z. has received
honoraria from AbbVie, Almirall, Basilea, Bayer Health Care,
Bioderma, Biogen-Idec, Dermira, Galderma, General Topics,
Glenmark, LEO Pharma, Philips Lifestyle, Pierre Fabre, Stiefel/
GlaxoSmithKline, Vichy and Xenon for participation on advisory
boards, or as a consultant, investigator or speaker. The
Departments of Dermatology, Venereology, Allergology and
Immunology, Dessau Medical Center, Dessau, Germany, have
received grants from AbbVie, AstraZeneca, Bioderma, Biogen-
Idec, Bristol-Meyers Squibb, Immundiagnostik, Intendis, LVMH,
Merz, Novartis, Pierre Fabre, and UCB for the participation of
C.C.Z. as an investigator, or on advisory boards.
PRIMER
20
|
2015
|
VOLUME 1 www.nature.com/nrdp
© 2015 Macmillan Publishers Limited. All rights reserved
Article
Full-text available
The epithelial–immune microenvironment (EIME) of epithelial tissues has five common elements: (1) microbial flora, (2) barrier, (3) epithelial cells, (4) immune cells, and (5) peripheral nerve endings. EIME provides both constant defense and situation-specific protective responses through three-layered mechanisms comprising barriers, innate immunity, and acquired immunity. The skin is one of the largest organs in the host defense system. The interactions between the five EIME elements of the skin protect against external dangers from the environment. This dysregulation can result in the generation of inflammatory loops in chronic inflammatory skin diseases. Here, we propose an understanding of EIME in chronic skin diseases, such as atopic dermatitis, psoriasis, systemic lupus erythematosus, alopecia areata, and acne vulgaris. We discuss the current treatment strategies targeting their inflammatory loops and propose possible therapeutic targets in the future.
Article
Full-text available
Cutibacterium acnes (C. acnes) is one of the most prevalent bacteria that forms the human skin microbiota. Specific phylotypes of C. acnes have been associated with the development of acne vulgaris, while other phylotypes have been linked to healthy skin. In this scenario, bacterial extracellular vesicles (EVs) play a role in the interkingdom communication role with the human host. The purpose of this study was to examine the impact of EVs generated by various phylotypes of C. acnes on inflammation and sebum production using different in vitro skin cell types. The main findings of this study reveal that the proteomic profile of the cargo embodied in the EVs reflects distinct characteristics of the different C. acnes phylotypes in terms of life cycle, survival, and virulence. The in vitro skin cell types showed an extended pro-inflammatory modulation of SLST A1 EVs consistently triggering the activation of the inflammation-related factors IL-8, IL-6, TNFα and GM-CSF, in comparison to SLST H1 and SLST H2. Additionally, an acne-prone skin model utilizing PCi-SEB and arachidonic acid as a sebum inducer, was employed to investigate the impact of C. acnes EVs on sebum regulation. Our findings indicated that all three types of EVs significantly inhibited sebum production after a 24-h treatment period, with SLST H1 EVs exhibiting the most pronounced inhibitory effect when compared to the positive control. The results of this study highlight the protective nature of C. acnes SLST H1 EVs and their potential use as a natural treatment option for alleviating symptoms associated with inflammation and oily skin.
Article
Full-text available
Background: Acne vulgaris is a common inflammatory disease of the pilosebaceous follicle that affects many teenagers and young people. There is an obvious need for topical treatments with good tolerability and efficacy for the management of acne lesions. Objective: This study determined the therapeutic efficacy of topical sodium hypochlorite solution (0.005%) in the treatment of mild to moderate acne lesions. Methods: This placebo-controlled randomized controlled trial compared 0.005% sodium hypochlorite to placebo administered topically on each side of the patients' faces 3 times a day for 1 month. The numbers of papules and pustules were recorded at baseline, 1, 2 and 4 weeks after initiation. Results: The total number of papules and pustules decreased after topical application of sodium hypochlorite 0.005% for 1 month. Conclusions: Topical sodium hypochlorite solution (0.005%) can be effective in the treatment of mild to moderate acne, and its clinical efficacy was evaluated between the male and female groups and between the hormonal and non-hormonal ones. Trial registration: Our study was registered in the Iranian Registry of Clinical Trials (IRCT) with the code number IRCT20200701047976N1.
Article
Lipid synthesis is necessary for formation of epithelial barriers and homeostasis with external microbes. An analysis of the response of human keratinocytes to several different commensal bacteria on the skin revealed that Cutibacterium acnes induced a large increase in essential lipids including triglycerides, ceramides, cholesterol, and free fatty acids. A similar response occurred in mouse epidermis and in human skin affected with acne. Further analysis showed that this increase in lipids was mediated by short-chain fatty acids produced by Cutibacterium acnes and was dependent on increased expression of several lipid synthesis genes including glycerol-3-phosphate-acyltransferase-3. Inhibition or RNA silencing of peroxisome proliferator-activated receptor-α (PPARα), but not PPARβ and PPARγ, blocked this response. The increase in keratinocyte lipid content improved innate barrier functions including antimicrobial activity, paracellular diffusion, and transepidermal water loss. These results reveal that metabolites from a common commensal bacterium have a previously unappreciated influence on the composition of epidermal lipids.
Article
A shift in the understanding of acne from a skin disease to a systemic, chronic inflammatory, lifestyle disease has fueled our curiosity about holistic ways to manage it. As with other noncommunicable diseases, long-term management needs a comprehensive approach. Apart from topical and systemic medications, changes in diet and lifestyle can help us achieve superior and long-lasting results. Moreover, as the biochemical pathways linking risk factors to acne are getting clearer, the potential prospect of early holistic management of acne preventing or delaying other lifestyle disorders such as obesity, diabetes, or cardiovascular disease is encouraging.
Article
Full-text available
Acne vulgaris is a common skin disease characterized by increased sebum production, inflammation, and Cutibacterium acnes (CA: formerly Propionibacterium acnes) hyperproliferation in pilosebaceous follicles. This study evaluated the efficacy of FRO, a formula composed of fermented Rhus verniciflua Stokes and Orostachys japonicus, against acne pathogenesis via antimicrobial assessment and an in vitro analysis. Stimulated model cells treated with hormones, CA, or lipopolysaccharide (LPS) were designed based on the characteristics of acne pathogenesis, including inflammation and sebum hypersecretion. High-performance liquid chromatography, disc diffusion, MTS, and western blotting assays were used to examine potential anti-acne effects. FRO was determined to contain phenolics such as gallic acid, fisetin, quercetin, and kaempferol. FRO exerted antimicrobial activity against CA and inhibited reactive oxygen species production that was otherwise increased by LPS or CA in HaCaT cells. Additionally, FRO exerted anti-inflammatory effects by inhibiting iNOS, TNF-α, IL-6, p-STAT-3, and p-NF-κB, which were previously upregulated by LPS or CA in THP-1 and HaCaT cells. FRO inhibited lipogenesis induced by steroid hormones and CA by decreasing FAS and SREBP-1 levels in sebocytes. Additionally, FRO down-regulated the androgen receptor, 5α-reductase, SREBP-1, and FAS levels, which were upregulated by steroid hormone in LNCaP cells. Taken together, our findings suggest that FRO alleviates acne by inhibiting the growth of CA, inflammation, and excess sebum and could be used for functional cosmetics or acne treatments.
Article
Objectives: Patients with acne usually develops acne scars subsequently, early intervention of scars is crucial in acne management. 1927nm fractional thulium fiber laser (TFL) is effective in scars improvement and chemical peels with 30% supramolecular salicylic acid (SSA) can be applied for the treatment of acne. The purpose of this study is to evaluate and compare the efficacy and safety of TFL monotherapy versus the concomitant application of TFL and 30% SSA on acne and acne scars. Materials and methods: Thirty-three patients with acne and acne scars were enrolled, and two sides of the face were randomly divided to receive either TFL and SSA chemical peeling or TFL. Four sessions of TFL treatments were applied with 4-week intervals for both sides, SSA combined treatment side received eight SSA chemical peels with 2-week intervals additionally. GAGS, ECCA score, the number of acne lesions, melanin index (MI) and erythema index (EI), transepidermal water loss (TEWL), and side effects were recorded at Weeks 0, 4, 8, 12, and 18. Satisfaction of patients was recorded on both sides at the end of the study. Results: Thirty patients completed the study. Both control group (TFL monotherapy) and SSA group (TFL combined with SSA chemical peeling) significantly improved GAGS and ECCA score. SSA group showed higher efficacy in terms of GAGS and ECCA score, acne lesion count, TEWL, MI, EI, and satisfaction than control group. All the side effects were temporary and tolerable, no adverse effects were observed. Conclusions: Both TFL and the TFL combined with 30% SSA chemical peeling are safe and effective for the treatment and prevention of acne and acne scars, though the combined group has higher efficacy.
Article
Background: The popularity of social media appears to be increasing the acceptance of cosmetic treatments, prompting more consumers to seek cosmetic treatments. As the estimated prevalence of acne vulgaris among adult women may be as high as 54%, acne is commonly observed among patients presenting for cosmetic treatments. Concomitant treatment of acne in the aesthetic patient population will improve overall clinical outcomes. Aims: The goal of this work was to deliver a high-quality ethical and evidence-based educational program to physicians and adjunctive health care providers to advance patient care. Methods: This paper is based on a webcam presentation with roundtable discussion by several notable experts in their field. Results: A range of topical medications, injectable products, chemical peels, and energy-based devices are available for treating acne vulgaris. In most instances, these are compatible with rejuvenation procedures in the aesthetic patient. Conclusion: The growth of social media is raising awareness of aesthetic procedures and appears to be increasing the number of patients seeking aesthetic treatment. Educating patients about the importance of treating acne vulgaris can improve overall treatment outcomes. In most instances, the presence of acne is not a barrier to aesthetic care.
Article
Introduction: Acne occurring in adults over the age of 25 years is known as acne tarda or adult acne. Three types of adult acne are recognized: persistent, late-onset, and recurrent acne. Most studies do not compare the characteristics between the three variants. In addition, little is known about adult acne in males. This study describes the epidemiological factors of adult acne and investigates certain triggering factors by sex and different types of adult acne. Methods: A multicenter, prospective, descriptive study was conducted. Patients with adult acne and an acne-free control group were compared regarding medical history, family history, smoking and drinking habits, and dietary factors. In addition, triggering and prognostic factors were investigated by sex and three different types of acne: persistent, late-onset, and recurrent acne. Results: The participants included 944 (88.56%) female and 122 (11.44%) male patients with adult acne, and 709 (73.85%) female and 251 (26.15%) male control patients. The consumption of crackers, chocolate, and pasta was significantly more common in the acne group than in the control group (p = 0.017, 0.002, and 0.040, respectively). Male patients with adult acne had a significantly longer disease duration than female patients with adult acne (p = 0.024). The most common type of acne was recurrent acne, followed by persistent and late-onset acne. Among patients with persistent acne, 14.5% had polycystic ovary syndrome (PCOS), whereas 12.2% of patients with recurrent acne and 11.1% of patients with late-onset acne had PCOS. Severe acne was more common in the persistent acne type (28.13%). The cheek (59.90%) was the most common involvement area, and stress (55.23%) was the most common triggering factor regardless of sex. Conclusions: Although adult female and male patents with adult acne share similar triggering factors, the involvement areas can differ, which may indicate the additional hormonal etiology of female adult acne. Further epidemiological studies on adult acne in both sexes may illuminate the pathogenesis of the disease, thus making possible the development of new treatment strategies.
Book
Acne vulgaris is an extraordinarily common, worldwide dis­ ease. Some see the disorder as merely cosmetic. Nonetheless, few skin diseases cause as much physical and psychological misery as this scourge of adolescence. Dermatologists of course have more than a passing familiar­ ity with acne vulgaris. Recognition is easy but there is still an extraordinary amount of controversy concerning causa­ tive factors and the best modes of treatment. Recent studies have brought forth some important findings about which practicing physicians know too little. This volume" ACNE: MORPHOGENESIS AND TREAT­ MENT" is a surprising book. What features make it so unique? This is the first complete account of the great diver­ sity of clinical manifestations. Moreover, gross morphology is coordinated with a thorough microscopic analysis of evolu­ tion of the disease. The material is presented in a readable and stimulating way. References are limited because they have been carefully selected. The authors emphasize that this richly illustrated work is intended for physicians who care for acne patients. Accord­ ingly, this is above all a practical treatise to assist doctors to diagnose and treat acne, and not only acne vulgaris but all the species of acne. This work is an overview of the entire acne problem with contributions from bacteriology, endocrinology, physiology, anatomy, immunology, cellular kinetics, and experimental acne. Above all it concludes with an optimistic presentation of therapeutic strategies which make it possible for the in­ formed physician to control the abominable effects of this distressing disorder.
Article
Several observations suggest that GH stimulates sebaceous gland growth and development. Therefore, we studied the effects of GH and insulin-like growth factors (IGFs), alone and with androgen, on sebaceous epithelial cell (sebocyte) growth and differentiation in vitro. The rat preputial cell culture model system was used to judge differentiation (induction of lipid-forming colonies, LFCs) and DNA synthesis. GH increased sebocyte differentiation. At a dose of 10−8 m in the presence of micromolar insulin, GH was 3.8 times more potent than IGF-I (38.1 ± 4.2%, sem, vs. 10 ± 1.5% LFCs) and 6 times more potent than IGF-II (6 ± 0.5% LFCs). IGF-I 10−8 m alone stimulated a similar amount of differentiation as insulin 10−6 m, although it was less effective than insulin in augmenting the effect of GH on differentiation. GH had no effect on sebocyte uptake of 3H-thymidine at doses up to 10−6 m. On the other hand, IGF-I was the most potent stimulus of DNA synthesis (168% of control; P < 0.001 vs. all others). IGF-II 1...
Article
Acne vulgaris, the most common disease of the skin, may present itself in a plethora of clinical forms, depending on the distribution, type of lesions, tendency to and manifestation of scarring, age at disease onset, and persistence of acne after the time of physiological regression [1]. The beginning of acne frequently occurs during the prepubertal period when adrenal androgens stimulate the pilosebaceous unit. Ovarian and testicular androgens play a key role in the development of acne in puberty. Consequently, acne vulgaris can begin in children as young as 6 or 7 years depending on the onset of adrenarche. Gradually, acne progresses in a cephalocaudal way resulting in the predominance of acne lesions on the chin, mandible, and neck just inferior to the mandible in adults and particularly adult women [2].
Article
Acne fulminans (also referred as acute febrile ulcerating acne conglobata with polyarthralgia and leukemoid reaction, or acne maligna) is a serious disease of sudden onset, associated with systemic symptoms and abnormal laboratory findings [1]. The term acne fulminans was coined by Plewig and Kligman in 1975 in order to describe acute febrile ulcerative acne conglobata with polyarthralgia and is considered a very uncommon complication of acne [2, 3].
Article
Acne vulgaris is a disorder that usually appears at puberty and resolves in late adolescence or early adult life. However, there are a significant number of adults who also suffer from acne. This chapter will review the epidemiology of adult acne, its etiology, pathogenesis, and clinical presentation, a suggested clinical and laboratory evaluation, and an approach to therapy. Adult acne can be divided into persistent acne which continues into adult life from the teen years and adult-onset acne which first appears after age 25 years. Much of the pathogenesis, clinical presentation, and therapy are comparable in both types and they will be discussed together.
Article
Acne vulgaris (acne) is a common inflammatory disorder of the cutaneous pilo-sebaceous unit. Here we perform a genome-wide association analysis in the United Kingdom, comparing severe cases of acne (n=1,893) with controls (n=5,132). In a second stage, we genotype putative-associated loci in a further 2,063 acne cases and 1,970 controls. We identify three genome-wide significant associations: 11q13.1 (rs478304, Pcombined =3.23 × 10 -11, odds ratio (OR)=1.20), 5q11.2 (rs38055, Pcombined =4.58 × 10-9, OR=1.17) and 1q41 (rs1159268, P combined =4.08 × 10-8, OR=1.17). All three loci contain genes linked to the TGFβ cell signalling pathway, namely OVOL1, FST and TGFB2. Transcripts of OVOL1 and TFGB2 have decreased expression in affected compared with normal skin. Collectively, these data support a key role for dysregulation of TGFβ-mediated signalling in susceptibility to acne.